BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012;72:5588-99. [PMID: 23118055 DOI: 10.1158/0008-5472.CAN-12-2753] [Cited by in Crossref: 977] [Cited by in F6Publishing: 591] [Article Influence: 108.6] [Reference Citation Analysis]
Number Citing Articles
1 de Sousa MML, Bjørås KØ, Hanssen-Bauer A, Solvang-Garten K, Otterlei M. p38 MAPK signaling and phosphorylations in the BRCT1 domain regulate XRCC1 recruitment to sites of DNA damage. Sci Rep 2017;7:6322. [PMID: 28740101 DOI: 10.1038/s41598-017-06770-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
2 Spiegel JO, Van Houten B, Durrant JD. PARP1: Structural insights and pharmacological targets for inhibition. DNA Repair (Amst) 2021;103:103125. [PMID: 33940558 DOI: 10.1016/j.dnarep.2021.103125] [Reference Citation Analysis]
3 Fang CB, Wu HT, Zhang ML, Liu J, Zhang GJ. Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Front Cell Dev Biol 2020;8:160. [PMID: 32300589 DOI: 10.3389/fcell.2020.00160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
4 Min R, Wu W, Wang M, Tang L, Chen D, Zhao H, Zhang C, Jiang Y. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer. Molecules 2019;24:E1901. [PMID: 31108884 DOI: 10.3390/molecules24101901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tavares TS, Hofman J, Lekešová A, Želazková J, Wsól V. Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. Cancers (Basel) 2020;12:E3127. [PMID: 33114555 DOI: 10.3390/cancers12113127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shen JP, Ideker T. Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls. J Mol Biol 2018;430:2900-12. [PMID: 29932943 DOI: 10.1016/j.jmb.2018.06.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
7 Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget 2017;8:48794-806. [PMID: 27447864 DOI: 10.18632/oncotarget.10720] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
8 Dickson BD, Wong WW, Wilson WR, Hay MP. Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors. Molecules 2019;24:E1559. [PMID: 31010230 DOI: 10.3390/molecules24081559] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Curtin NJ. The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity. Cancers (Basel) 2020;12:E564. [PMID: 32121331 DOI: 10.3390/cancers12030564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS One 2015;10:e0125482. [PMID: 25965342 DOI: 10.1371/journal.pone.0125482] [Cited by in Crossref: 76] [Cited by in F6Publishing: 59] [Article Influence: 12.7] [Reference Citation Analysis]
11 Liu X, Jiang Y, Nowak B, Hargis S, Plunkett W. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. Mol Cancer Ther 2016;15:2302-13. [PMID: 27474148 DOI: 10.1158/1535-7163.MCT-15-0801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A, Wong KK. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Ther Adv Med Oncol 2018;10:1758835918808509. [PMID: 30542378 DOI: 10.1177/1758835918808509] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
13 Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl 2013;15:342-9. [PMID: 23584378 DOI: 10.1038/aja.2013.38] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
14 Gorbunova V, Beck JT, Hofheinz RD, Garcia-Alfonso P, Nechaeva M, Cubillo Gracian A, Mangel L, Elez Fernandez E, Deming DA, Ramanathan RK, Torres AH, Sullivan D, Luo Y, Berlin JD. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Br J Cancer 2019;120:183-9. [PMID: 30531832 DOI: 10.1038/s41416-018-0343-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
15 Liptay M, Barbosa JS, Rottenberg S. Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers. Front Oncol 2020;10:670. [PMID: 32432041 DOI: 10.3389/fonc.2020.00670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. PLoS One 2015;10:e0118187. [PMID: 25689628 DOI: 10.1371/journal.pone.0118187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
17 Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther 2020;213:107588. [PMID: 32450190 DOI: 10.1016/j.pharmthera.2020.107588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
18 Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol 2015;47:262-8. [PMID: 25975349 DOI: 10.3892/ijo.2015.3003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
19 Patel PS, Algouneh A, Hakem R. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene 2021;40:3001-14. [PMID: 33716297 DOI: 10.1038/s41388-021-01744-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
20 Amuzu S, Carmona E, Mes-Masson AM, Greenwood CMT, Tonin PN, Ragoussis J. Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. Cancers (Basel) 2021;13:1296. [PMID: 33803939 DOI: 10.3390/cancers13061296] [Reference Citation Analysis]
21 Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 2018;81:255-67. [PMID: 29189915 DOI: 10.1007/s00280-017-3483-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer 2021;124:552-63. [PMID: 33106584 DOI: 10.1038/s41416-020-01114-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
23 Garje R, Vaddepally RK, Zakharia Y. PARP Inhibitors in Prostate and Urothelial Cancers. Front Oncol 2020;10:114. [PMID: 32117762 DOI: 10.3389/fonc.2020.00114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
24 Mechetin GV, Endutkin AV, Diatlova EA, Zharkov DO. Inhibitors of DNA Glycosylases as Prospective Drugs. Int J Mol Sci 2020;21:E3118. [PMID: 32354123 DOI: 10.3390/ijms21093118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
25 Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179. [PMID: 27884198 DOI: 10.1186/s13046-016-0456-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 11.2] [Reference Citation Analysis]
26 Liu JF, Matulonis UA. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep 2016;18:29. [PMID: 26984416 DOI: 10.1007/s11912-016-0515-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
27 Ding X, Ray Chaudhuri A, Callen E, Pang Y, Biswas K, Klarmann KD, Martin BK, Burkett S, Cleveland L, Stauffer S, Sullivan T, Dewan A, Marks H, Tubbs AT, Wong N, Buehler E, Akagi K, Martin SE, Keller JR, Nussenzweig A, Sharan SK. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies. Nat Commun 2016;7:12425. [PMID: 27498558 DOI: 10.1038/ncomms12425] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 16.8] [Reference Citation Analysis]
28 Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget 2018;9:3908-21. [PMID: 29423093 DOI: 10.18632/oncotarget.23386] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
29 Robert C, Nagaria PK, Pawar N, Adewuyi A, Gojo I, Meyers DJ, Cole PA, Rassool FV. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. Leuk Res 2016;45:14-23. [PMID: 27064363 DOI: 10.1016/j.leukres.2016.03.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
30 Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Chen S, Huang Z, Zheng X, Huang D, Hu Y. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. Clin Med Insights Oncol 2021;15:1179554921996288. [PMID: 33737855 DOI: 10.1177/1179554921996288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
31 Morris C, Durand S, Jalinot P. Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1. Oncotarget 2021;12:649-64. [PMID: 33868586 DOI: 10.18632/oncotarget.27923] [Reference Citation Analysis]
32 Giovannini S, Weller MC, Repmann S, Moch H, Jiricny J. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. Nucleic Acids Res 2019;47:9132-43. [PMID: 31329989 DOI: 10.1093/nar/gkz624] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
33 Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer 2019:ijgc-2019-000499. [PMID: 31118216 DOI: 10.1136/ijgc-2019-000499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs 2017;77:113-30. [PMID: 28078645 DOI: 10.1007/s40265-016-0688-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
35 Castells-Roca L, Tejero E, Rodríguez-Santiago B, Surrallés J. CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer. Cancers (Basel) 2021;13:1591. [PMID: 33808217 DOI: 10.3390/cancers13071591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Palazzo L, Ahel I. PARPs in genome stability and signal transduction: implications for cancer therapy. Biochem Soc Trans 2018;46:1681-95. [PMID: 30420415 DOI: 10.1042/BST20180418] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 10.3] [Reference Citation Analysis]
37 Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev 2013;32:723-61. [PMID: 24043487 DOI: 10.1007/s10555-013-9447-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
38 Borazanci E, Korn R, Liang WS, Guarnieri C, Haag S, Snyder C, Hendrickson K, Caldwell L, Von Hoff D, Jameson G. An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. Oncologist. 2020;25:e60-e67. [PMID: 31391296 DOI: 10.1634/theoncologist.2018-0905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Buck J, Dyer PJC, Hii H, Carline B, Kuchibhotla M, Byrne J, Howlett M, Whitehouse J, Ebert MA, McDonald KL, Gottardo NG, Endersby R. Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma. Front Mol Biosci 2021;8:633344. [PMID: 33996894 DOI: 10.3389/fmolb.2021.633344] [Reference Citation Analysis]
40 Brosh RM Jr. DNA helicases involved in DNA repair and their roles in cancer. Nat Rev Cancer 2013;13:542-58. [PMID: 23842644 DOI: 10.1038/nrc3560] [Cited by in Crossref: 203] [Cited by in F6Publishing: 175] [Article Influence: 25.4] [Reference Citation Analysis]
41 Horton JK, Wilson SH. Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity. Front Oncol 2013;3:257. [PMID: 24137565 DOI: 10.3389/fonc.2013.00257] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
42 Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol 2018;10:1758835918778483. [PMID: 29977351 DOI: 10.1177/1758835918778483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
43 Bian C, Zhang C, Luo T, Vyas A, Chen SH, Liu C, Kassab MA, Yang Y, Kong M, Yu X. NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun 2019;10:693. [PMID: 30741937 DOI: 10.1038/s41467-019-08530-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
44 Stingele J, Bellelli R, Boulton SJ. Mechanisms of DNA-protein crosslink repair. Nat Rev Mol Cell Biol 2017;18:563-73. [PMID: 28655905 DOI: 10.1038/nrm.2017.56] [Cited by in Crossref: 114] [Cited by in F6Publishing: 85] [Article Influence: 28.5] [Reference Citation Analysis]
45 Gout J, Perkhofer L, Morawe M, Arnold F, Ihle M, Biber S, Lange S, Roger E, Kraus JM, Stifter K, Hahn SA, Zamperone A, Engleitner T, Müller M, Walter K, Rodriguez-Aznar E, Sainz B Jr, Hermann PC, Hessmann E, Müller S, Azoitei N, Lechel A, Liebau S, Wagner M, Simeone DM, Kestler HA, Seufferlein T, Wiesmüller L, Rad R, Frappart PO, Kleger A. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut 2021;70:743-60. [PMID: 32873698 DOI: 10.1136/gutjnl-2019-319970] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
46 Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer 2019;19:44. [PMID: 30630446 DOI: 10.1186/s12885-018-5250-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
47 Rudolph J, Mahadevan J, Dyer P, Luger K. Poly(ADP-ribose) polymerase 1 searches DNA via a 'monkey bar' mechanism. Elife 2018;7:e37818. [PMID: 30088474 DOI: 10.7554/eLife.37818] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
48 Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer 2021. [PMID: 34294893 DOI: 10.1038/s41416-021-01476-w] [Reference Citation Analysis]
49 McGonigle S, Chen Z, Wu J, Chang P, Kolber-Simonds D, Ackermann K, Twine NC, Shie JL, Miu JT, Huang KC, Moniz GA, Nomoto K. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget 2015;6:41307-23. [PMID: 26513298 DOI: 10.18632/oncotarget.5846] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
50 Sussman TA, Funchain P, Singh A. Clinical Trials in Metastatic Uveal Melanoma: Current Status. Ocul Oncol Pathol 2020;6:381-7. [PMID: 33447587 DOI: 10.1159/000508383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Milanesio MC, Giordano S, Valabrega G. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Cancers (Basel) 2020;12:E1315. [PMID: 32455819 DOI: 10.3390/cancers12051315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
52 Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, Lash BW, Leach JW, Leal TB, Aggarwal C, Ramalingam SS. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol 2019;37:222-9. [PMID: 30523756 DOI: 10.1200/JCO.18.00264] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 18.3] [Reference Citation Analysis]
53 Putri JF, Bhargava P, Dhanjal JK, Yaguchi T, Sundar D, Kaul SC, Wadhwa R. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers. J Exp Clin Cancer Res 2019;38:499. [PMID: 31856867 DOI: 10.1186/s13046-019-1500-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
54 Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol 2018;19:1. [PMID: 30535808 DOI: 10.1007/s11864-018-0572-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
55 Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. Diagnostics (Basel) 2019;9:E87. [PMID: 31374917 DOI: 10.3390/diagnostics9030087] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 21.0] [Reference Citation Analysis]
56 Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. Br J Cancer. 2018;118:938-946. [PMID: 29527010 DOI: 10.1038/s41416-018-0003-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
57 Jannetti SA, Zeglis BM, Zalutsky MR, Reiner T. Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. Front Pharmacol 2020;11:170. [PMID: 32194409 DOI: 10.3389/fphar.2020.00170] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
58 Parvin S, Ramirez-Labrada A, Aumann S, Lu X, Weich N, Santiago G, Cortizas EM, Sharabi E, Zhang Y, Sanchez-Garcia I, Gentles AJ, Roberts E, Bilbao-Cortes D, Vega F, Chapman JR, Verdun RE, Lossos IS. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. Cancer Cell 2019;36:237-249.e6. [PMID: 31447348 DOI: 10.1016/j.ccell.2019.07.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
59 Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, Zhao M, Yang Q, Wang Y, Yang X. Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. Front Oncol 2020;10:954. [PMID: 32719741 DOI: 10.3389/fonc.2020.00954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Munasinghe W, Stodtmann S, Tolcher A, Calvo E, Gordon M, Jalving M, de Vos-Geelen J, Medina D, Bergau D, Nuthalapati S, Hoffman D, Shepherd S, Xiong H. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. Cancer Chemother Pharmacol 2016;78:1003-11. [PMID: 27709282 DOI: 10.1007/s00280-016-3156-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
61 Hsu A, Chudasama R, Almhanna K, Raufi A. Targeted therapies for gastroesophageal cancers. Ann Transl Med 2020;8:1104. [PMID: 33145323 DOI: 10.21037/atm-20-3265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Toma M, Sullivan-Reed K, Śliwiński T, Skorski T. RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies. Cancers (Basel) 2019;11:E1561. [PMID: 31615159 DOI: 10.3390/cancers11101561] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
63 Toren PJ, Gleave ME. Novel non-AR therapeutic targets in castrate resistant prostate cancer. Transl Androl Urol 2013;2:265-77. [PMID: 26816739 DOI: 10.3978/j.issn.2223-4683.2013.09.09] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
64 Calvo JA, Moroski-Erkul CA, Lake A, Eichinger LW, Shah D, Jhun I, Limsirichai P, Bronson RT, Christiani DC, Meira LB, Samson LD. Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1. PLoS Genet 2013;9:e1003413. [PMID: 23593019 DOI: 10.1371/journal.pgen.1003413] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
65 Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res 2017;23:523-35. [PMID: 27440269 DOI: 10.1158/1078-0432.CCR-16-1040] [Cited by in Crossref: 126] [Cited by in F6Publishing: 75] [Article Influence: 25.2] [Reference Citation Analysis]
66 Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol 2019;12:871-8. [PMID: 31075528 DOI: 10.1016/j.tranon.2019.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
67 Ruiz PD, Hamilton GA, Park JW, Gamble MJ. MacroH2A1 Regulation of Poly(ADP-Ribose) Synthesis and Stability Prevents Necrosis and Promotes DNA Repair. Mol Cell Biol 2019;40:e00230-19. [PMID: 31636161 DOI: 10.1128/MCB.00230-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
68 Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M. Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast. Oncotarget 2018;9:36379-91. [PMID: 30555636 DOI: 10.18632/oncotarget.26372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Wilson TC, Pillarsetty N, Reiner T. A one-pot radiosynthesis of [18 F]PARPi. J Labelled Comp Radiopharm 2020;63:419-25. [PMID: 32391930 DOI: 10.1002/jlcr.3847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Siri SO, Martino J, Gottifredi V. Structural Chromosome Instability: Types, Origins, Consequences, and Therapeutic Opportunities. Cancers (Basel) 2021;13:3056. [PMID: 34205328 DOI: 10.3390/cancers13123056] [Reference Citation Analysis]
71 Chugh R, Ballman KV, Helman LJ, Patel S, Whelan JS, Widemann B, Lu Y, Hawkins DS, Mascarenhas L, Glod JW, Ji J, Zhang Y, Reinke D, Strauss SJ. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer 2021;127:1301-10. [PMID: 33289920 DOI: 10.1002/cncr.33349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
72 Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr 2020;4:pkz085. [PMID: 32337496 DOI: 10.1093/jncics/pkz085] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
73 Schulz P, Jansseune K, Degenkolbe T, Méret M, Claeys H, Skirycz A, Teige M, Willmitzer L, Hannah MA. Poly(ADP-ribose)polymerase activity controls plant growth by promoting leaf cell number. PLoS One 2014;9:e90322. [PMID: 24587323 DOI: 10.1371/journal.pone.0090322] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
74 Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. Oncologist 2021;26:e115-29. [PMID: 32790034 DOI: 10.1634/theoncologist.2020-0697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
75 Tsuda M, Ogawa S, Ooka M, Kobayashi K, Hirota K, Wakasugi M, Matsunaga T, Sakuma T, Yamamoto T, Chikuma S, Sasanuma H, Debatisse M, Doherty AJ, Fuchs RP, Takeda S. PDIP38/PolDIP2 controls the DNA damage tolerance pathways by increasing the relative usage of translesion DNA synthesis over template switching. PLoS One 2019;14:e0213383. [PMID: 30840704 DOI: 10.1371/journal.pone.0213383] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
76 McLaughlin LJ, Stojanovic L, Kogan AA, Rutherford JL, Choi EY, Yen RC, Xia L, Zou Y, Lapidus RG, Baylin SB, Topper MJ, Rassool FV. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency. Proc Natl Acad Sci U S A 2020;117:17785-95. [PMID: 32651270 DOI: 10.1073/pnas.2003499117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
77 Ávila-Arroyo S, Nuñez GS, García-Fernández LF, Galmarini CM. Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines. J Breast Cancer 2015;18:329-38. [PMID: 26770239 DOI: 10.4048/jbc.2015.18.4.329] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
78 Horton JR, Woodcock CB, Chen Q, Liu X, Zhang X, Shanks J, Rai G, Mott BT, Jansen DJ, Kales SC, Henderson MJ, Cyr M, Pohida K, Hu X, Shah P, Xu X, Jadhav A, Maloney DJ, Hall MD, Simeonov A, Fu H, Vertino PM, Cheng X. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. J Med Chem 2018;61:10588-601. [PMID: 30392349 DOI: 10.1021/acs.jmedchem.8b01219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
79 Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 2016;160:65-83. [PMID: 26896565 DOI: 10.1016/j.pharmthera.2016.02.003] [Cited by in Crossref: 195] [Cited by in F6Publishing: 159] [Article Influence: 39.0] [Reference Citation Analysis]
80 Feng FY, Brenner JC, Hussain M, Chinnaiyan AM. Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res. 2014;20:4442-4448. [PMID: 24958807 DOI: 10.1158/1078-0432.ccr-13-0275] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
81 Sabbatino F, Liguori L, Malapelle U, Schiavi F, Tortora V, Conti V, Filippelli A, Tortora G, Ferrone CR, Pepe S. Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. Front Oncol 2020;10:567289. [PMID: 33330039 DOI: 10.3389/fonc.2020.567289] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Camero S, Ceccarelli S, De Felice F, Marampon F, Mannarino O, Camicia L, Vescarelli E, Pontecorvi P, Pizer B, Shukla R, Schiavetti A, Mollace MG, Pizzuti A, Tombolini V, Marchese C, Megiorni F, Dominici C. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines. J Cancer Res Clin Oncol 2019;145:137-52. [PMID: 30357520 DOI: 10.1007/s00432-018-2774-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
83 Ummarino S, Hausman C, Di Ruscio A. The PARP Way to Epigenetic Changes. Genes (Basel) 2021;12:446. [PMID: 33804735 DOI: 10.3390/genes12030446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
84 Ronson GE, Piberger AL, Higgs MR, Olsen AL, Stewart GS, McHugh PJ, Petermann E, Lakin ND. PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. Nat Commun 2018;9:746. [PMID: 29467415 DOI: 10.1038/s41467-018-03159-2] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 24.7] [Reference Citation Analysis]
85 Grundy MK, Buckanovich RJ, Bernstein KA. Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer 2020;2:zcaa024. [PMID: 33015624 DOI: 10.1093/narcan/zcaa024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
86 Hu Y, Petit SA, Ficarro SB, Toomire KJ, Xie A, Lim E, Cao SA, Park E, Eck MJ, Scully R, Brown M, Marto JA, Livingston DM. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov 2014;4:1430-47. [PMID: 25252691 DOI: 10.1158/2159-8290.CD-13-0891] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
87 Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 2017;9:eaal5148. [PMID: 28566428 DOI: 10.1126/scitranslmed.aal5148] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 27.7] [Reference Citation Analysis]
88 Kühbacher U, Duxin JP. How to fix DNA-protein crosslinks. DNA Repair (Amst) 2020;94:102924. [PMID: 32683310 DOI: 10.1016/j.dnarep.2020.102924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
89 Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells. PLoS One 2016;11:e0159341. [PMID: 27428646 DOI: 10.1371/journal.pone.0159341] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
90 Zeng Y, Rucki AA, Che X, Zheng L. Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:441-8. [PMID: 28736631 DOI: 10.21037/jgo.2016.10.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. Front Oncol 2021;11:686776. [PMID: 34262869 DOI: 10.3389/fonc.2021.686776] [Reference Citation Analysis]
92 Zhen Y, Yu Y. Proteomic Analysis of the Downstream Signaling Network of PARP1. Biochemistry 2018;57:429-40. [PMID: 29327913 DOI: 10.1021/acs.biochem.7b01022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
93 Ogden TEH, Yang JC, Schimpl M, Easton LE, Underwood E, Rawlins PB, McCauley MM, Langelier MF, Pascal JM, Embrey KJ, Neuhaus D. Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition. Nucleic Acids Res 2021;49:2266-88. [PMID: 33511412 DOI: 10.1093/nar/gkab020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Das SK, Rehman I, Ghosh A, Sengupta S, Majumdar P, Jana B, Das BB. Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells. Nucleic Acids Res 2016;44:8363-75. [PMID: 27466387 DOI: 10.1093/nar/gkw665] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
95 Wu M, Wang X, McGregor N, Pienta KJ, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol 2014;85:866-76. [PMID: 24627085 DOI: 10.1124/mol.113.090688] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
96 Zhang H, Xiong Y, Chen J. DNA-protein cross-link repair: what do we know now? Cell Biosci 2020;10:3. [PMID: 31921408 DOI: 10.1186/s13578-019-0366-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
97 Grundy GJ, Parsons JL. Base excision repair and its implications to cancer therapy. Essays Biochem 2020;64:831-43. [PMID: 32648895 DOI: 10.1042/EBC20200013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
98 Yang X, Ndawula C Jr, Zhou H, Gong X, Jin J. JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib. Oncol Lett 2015;9:757-61. [PMID: 25621047 DOI: 10.3892/ol.2014.2762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
99 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
100 Hammel P, Vitellius C, Boisteau É, Wisniewski M, Colle E, Hilmi M, Dengremont C, Granier S, Turpin A, de Mestier L, Neuzillet C. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Ther Adv Med Oncol 2020;12:1758835920937949. [PMID: 32695234 DOI: 10.1177/1758835920937949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther 2019;201:94-102. [PMID: 31128155 DOI: 10.1016/j.pharmthera.2019.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 25.0] [Reference Citation Analysis]
102 Horton JK, Stefanick DF, Gassman NR, Williams JG, Gabel SA, Cuneo MJ, Prasad R, Kedar PS, Derose EF, Hou EW, London RE, Wilson SH. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. DNA Repair (Amst) 2013;12:774-85. [PMID: 23871146 DOI: 10.1016/j.dnarep.2013.06.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
103 Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol Oncol 2019;155:144-50. [PMID: 31434613 DOI: 10.1016/j.ygyno.2019.08.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
104 Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers (Basel) 2020;12:E916. [PMID: 32276534 DOI: 10.3390/cancers12040916] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 42.0] [Reference Citation Analysis]
105 Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leuk Lymphoma 2019;60:1098-101. [PMID: 30277116 DOI: 10.1080/10428194.2018.1520988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 2015;8:519-28. [PMID: 25750544 DOI: 10.2147/OTT.S30793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
107 Hintelmann K, Kriegs M, Rothkamm K, Rieckmann T. Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting. Front Oncol 2020;10:1260. [PMID: 32903756 DOI: 10.3389/fonc.2020.01260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
108 Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ. Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Oncotarget 2015;6:10746-58. [PMID: 25883215 DOI: 10.18632/oncotarget.3628] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
109 Takahashi N, Surolia I, Thomas A. Targeting DNA Repair to Drive Immune Responses: It's Time to Reconsider the Strategy for Clinical Translation. Clin Cancer Res 2020;26:2452-6. [PMID: 32066627 DOI: 10.1158/1078-0432.CCR-19-3841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
110 Abecassis I, Sedgewick AJ, Romkes M, Buch S, Nukui T, Kapetanaki MG, Vogt A, Kirkwood JM, Benos PV, Tawbi H. PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep 2019;9:3309. [PMID: 30824778 DOI: 10.1038/s41598-019-39542-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
111 Novohradsky V, Zajac J, Vrana O, Kasparkova J, Brabec V. Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. Oncotarget 2018;9:28456-73. [PMID: 29983873 DOI: 10.18632/oncotarget.25466] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
112 Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer 2014;61:145-50. [PMID: 24038812 DOI: 10.1002/pbc.24697] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
113 Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L. Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. Cancer Manag Res 2021;13:3081-100. [PMID: 33854378 DOI: 10.2147/CMAR.S292992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context 2018;7:212540. [PMID: 30116283 DOI: 10.7573/dic.212540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
115 Wang J, Oh YT, Li Z, Dou J, Tang S, Wang X, Wang H, Takeda S, Wang Y. RAD52 Adjusts Repair of Single-Strand Breaks via Reducing DNA-Damage-Promoted XRCC1/LIG3α Co-localization. Cell Rep 2021;34:108625. [PMID: 33440161 DOI: 10.1016/j.celrep.2020.108625] [Reference Citation Analysis]
116 Li S, Zhang Y, Wang N, Guo R, Liu Q, Lv C, Wang J, Wang L, Yang QK. Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. Cell Death Dis 2020;11:219. [PMID: 32249776 DOI: 10.1038/s41419-020-2408-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
117 Ghosh R, Roy S, Kamyab J, Danzter F, Franco S. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways. DNA Repair (Amst) 2016;45:56-62. [PMID: 27373144 DOI: 10.1016/j.dnarep.2016.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
118 Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J 2021;40:e106700. [PMID: 33439509 DOI: 10.15252/embj.2020106700] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
119 Zhang J, Dai Q, Park D, Deng X. Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) 2016;7:E51. [PMID: 27548226 DOI: 10.3390/genes7080051] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 9.4] [Reference Citation Analysis]
120 Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91. [PMID: 25818403 DOI: 10.1016/j.ygyno.2015.03.042] [Cited by in Crossref: 155] [Cited by in F6Publishing: 143] [Article Influence: 25.8] [Reference Citation Analysis]
121 Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med 2018;10:e9172. [PMID: 30377213 DOI: 10.15252/emmm.201809172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 32.0] [Reference Citation Analysis]
122 Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES. An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast Cancer Res 2021;23:30. [PMID: 33663560 DOI: 10.1186/s13058-021-01408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open 2020;3:e2021692. [PMID: 33112397 DOI: 10.1001/jamanetworkopen.2020.21692] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
124 Zhou C, Parsons JL. The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma. Expert Rev Mol Med 2020;22:e3. [PMID: 32611474 DOI: 10.1017/erm.2020.4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
125 Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors. Cancer Cell 2019;35:519-533.e8. [PMID: 30889383 DOI: 10.1016/j.ccell.2019.02.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
126 Alagoz M, Wells OS, El-Khamisy SF. TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy. Nucleic Acids Res 2014;42:3089-103. [PMID: 24335147 DOI: 10.1093/nar/gkt1260] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
127 Abe T, Branzei D. High levels of BRC4 induced by a Tet-On 3G system suppress DNA repair and impair cell proliferation in vertebrate cells. DNA Repair (Amst) 2014;22:153-64. [PMID: 25218467 DOI: 10.1016/j.dnarep.2014.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
128 Lee EK, Matulonis UA. PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. Cancers (Basel) 2020;12:E2054. [PMID: 32722408 DOI: 10.3390/cancers12082054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
129 Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG. Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol 2016;6:24. [PMID: 26909338 DOI: 10.3389/fonc.2016.00024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
130 Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci Adv 2020;6:eaaz3221. [PMID: 32494639 DOI: 10.1126/sciadv.aaz3221] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 21.0] [Reference Citation Analysis]
131 Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG. Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models. J Cell Mol Med 2020;24:10420-31. [PMID: 32686903 DOI: 10.1111/jcmm.15655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
132 Harrision D, Gravells P, Thompson R, Bryant HE. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy. Front Mol Biosci 2020;7:191. [PMID: 33005627 DOI: 10.3389/fmolb.2020.00191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
133 Ruggiano A, Ramadan K. DNA-protein crosslink proteases in genome stability. Commun Biol 2021;4:11. [PMID: 33398053 DOI: 10.1038/s42003-020-01539-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
134 Exman P, Barroso-Sousa R, Tolaney SM. Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther 2019;12:5177-87. [PMID: 31303769 DOI: 10.2147/OTT.S184971] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
135 Gonçalves A, Bertucci A, Bertucci F. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond? Cancers (Basel) 2020;12:E1378. [PMID: 32471249 DOI: 10.3390/cancers12061378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
136 Yip HYK, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells 2021;10:659. [PMID: 33809714 DOI: 10.3390/cells10030659] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Mol Cancer 2017;16:86. [PMID: 28454547 DOI: 10.1186/s12943-017-0652-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
138 Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res 2013;73:6254-63. [PMID: 23966292 DOI: 10.1158/0008-5472.CAN-13-0044] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
139 Thumser-Henner P, Nytko KJ, Rohrer Bley C. Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy. BMC Vet Res 2020;16:30. [PMID: 32005245 DOI: 10.1186/s12917-020-2247-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
140 Papa A, Caruso D, Strudel M, Tomao S, Tomao F. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med 2016;14:267. [PMID: 27634150 DOI: 10.1186/s12967-016-1027-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
141 Lehman JM, Gwin ME, Massion PP. Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. Curr Oncol Rep 2017;19:49. [PMID: 28643173 DOI: 10.1007/s11912-017-0609-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
142 OʼSullivan Coyne G, Chen A, Kummar S. Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol 2015;27:475-81. [PMID: 26447876 DOI: 10.1097/CCO.0000000000000238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
143 Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21:162-74. [PMID: 31806540 DOI: 10.1016/S1470-2045(19)30684-9] [Cited by in Crossref: 178] [Cited by in F6Publishing: 76] [Article Influence: 89.0] [Reference Citation Analysis]
144 Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D. PARP inhibition causes premature loss of cohesion in cancer cells. Oncotarget 2017;8:103931-51. [PMID: 29262611 DOI: 10.18632/oncotarget.21879] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
145 Harvey A, Mielke N, Grimstead JW, Jones RE, Nguyen T, Mueller M, Baird DM, Hendrickson EA. PARP1 is required for preserving telomeric integrity but is dispensable for A-NHEJ. Oncotarget 2018;9:34821-37. [PMID: 30410680 DOI: 10.18632/oncotarget.26201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
146 Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma 2017;58:2705-16. [PMID: 28394191 DOI: 10.1080/10428194.2017.1306647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
147 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373:1697-1708. [PMID: 26510020 DOI: 10.1056/nejmoa1506859] [Cited by in Crossref: 1229] [Cited by in F6Publishing: 625] [Article Influence: 204.8] [Reference Citation Analysis]
148 Wang L, Liang C, Li F, Guan D, Wu X, Fu X, Lu A, Zhang G. PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. Int J Mol Sci 2017;18:E2111. [PMID: 28991194 DOI: 10.3390/ijms18102111] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
149 Mangoni M, Sottili M, Salvatore G, Campanacci D, Scoccianti G, Beltrami G, Delli Paoli C, Dominici L, Maragna V, Olmetto E, Meattini I, Desideri I, Bonomo P, Greto D, Livi L. Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors? Radiol Med 2019;124:282-9. [PMID: 29582320 DOI: 10.1007/s11547-018-0877-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
150 O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol. 2014;4:42. [PMID: 24616882 DOI: 10.3389/fonc.2014.00042] [Cited by in Crossref: 35] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
151 Saquilabon Cruz GM, Kong X, Silva BA, Khatibzadeh N, Thai R, Berns MW, Yokomori K. Femtosecond near-infrared laser microirradiation reveals a crucial role for PARP signaling on factor assemblies at DNA damage sites. Nucleic Acids Res 2016;44:e27. [PMID: 26424850 DOI: 10.1093/nar/gkv976] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
152 Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer. Oncogene 2021;40:3845-58. [PMID: 33966038 DOI: 10.1038/s41388-021-01788-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Quiñones JL, Thapar U, Wilson SH, Ramsden DA, Demple B. Oxidative DNA-protein crosslinks formed in mammalian cells by abasic site lyases involved in DNA repair. DNA Repair (Amst) 2020;87:102773. [PMID: 31945542 DOI: 10.1016/j.dnarep.2019.102773] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
154 Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 2014;9:829-41. [PMID: 25437539 DOI: 10.1016/j.celrep.2014.09.028] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 15.4] [Reference Citation Analysis]
155 Sen T, Gay CM, Byers LA. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Transl Lung Cancer Res 2018;7:50-68. [PMID: 29535912 DOI: 10.21037/tlcr.2018.02.03] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 14.0] [Reference Citation Analysis]
156 Thomas A, Murai J, Pommier Y. The evolving landscape of predictive biomarkers of response to PARP inhibitors. J Clin Invest 2018;128:1727-30. [PMID: 29664016 DOI: 10.1172/JCI120388] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
157 George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol 2017;14:284-96. [PMID: 27958297 DOI: 10.1038/nrclinonc.2016.191] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 18.0] [Reference Citation Analysis]
158 Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G. Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer. J Transl Med 2017;15:199. [PMID: 28969705 DOI: 10.1186/s12967-017-1296-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
159 Bixel K, Hays JL. Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 2015;8:127-35. [PMID: 26309417 DOI: 10.2147/PGPM.S62809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
160 Liu Y, Yin X, Zhong J, Guan N, Luo Z, Min L, Yao X, Bo X, Dai L, Bai H. Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference Transcriptomes. Genes (Basel) 2017;8:E86. [PMID: 28245581 DOI: 10.3390/genes8030086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
161 Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2016;78:525-31. [PMID: 27422301 DOI: 10.1007/s00280-016-3106-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
162 Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer 2020;19:49. [PMID: 32122376 DOI: 10.1186/s12943-020-01167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 40.0] [Reference Citation Analysis]
163 Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res 2015;3:1257-68. [PMID: 26138335 DOI: 10.1158/2326-6066.CIR-15-0044] [Cited by in Crossref: 161] [Cited by in F6Publishing: 93] [Article Influence: 26.8] [Reference Citation Analysis]
164 Krüger A, Bürkle A, Hauser K, Mangerich A. Real-time monitoring of PARP1-dependent PARylation by ATR-FTIR spectroscopy. Nat Commun 2020;11:2174. [PMID: 32358582 DOI: 10.1038/s41467-020-15858-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
165 Banerjee T, Aggarwal M, Brosh RM Jr. A new development in DNA repair modulation: discovery of a BLM helicase inhibitor. Cell Cycle 2013;12:713-4. [PMID: 23422862 DOI: 10.4161/cc.23953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
166 Ghosh S, Sur S, Yerram SR, Rago C, Bhunia AK, Hossain MZ, Paun BC, Ren YR, Iacobuzio-Donahue CA, Azad NA, Kern SE. Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genes. Am J Pathol 2014;184:260-70. [PMID: 24200853 DOI: 10.1016/j.ajpath.2013.09.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
167 Yang Y, Du N, Xie L, Jiang J, Mo J, Hong J, Mao D, Ng DM, Shi H. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World J Surg Oncol 2020;18:151. [PMID: 32622363 DOI: 10.1186/s12957-020-01931-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Reuvers TGA, Kanaar R, Nonnekens J. DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. Cancers (Basel) 2020;12:E2098. [PMID: 32731592 DOI: 10.3390/cancers12082098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
169 Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer S, Hermann M, Skvortsova I, Vrbkova J, Bouchal J, Culig Z, Santer FR. Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. Mol Oncol 2018;12:561-76. [PMID: 29465803 DOI: 10.1002/1878-0261.12185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
170 Allocca M, Corrigan JJ, Fake KR, Calvo JA, Samson LD. PARP inhibitors protect against sex- and AAG-dependent alkylation-induced neural degeneration. Oncotarget 2017;8:68707-20. [PMID: 28978150 DOI: 10.18632/oncotarget.19844] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
171 Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med 2021;53:42-51. [PMID: 33487630 DOI: 10.1038/s12276-021-00557-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
172 Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P. First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research. Cancer Manag Res 2020;12:5479-89. [PMID: 32765062 DOI: 10.2147/CMAR.S194874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
173 Dellomo AJ, Baer MR, Rassool FV. Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. Cancer Lett 2019;454:171-8. [PMID: 30953707 DOI: 10.1016/j.canlet.2019.03.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
174 Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Rep 2019;27:3422-3432.e4. [PMID: 31216465 DOI: 10.1016/j.celrep.2019.05.058] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
175 Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget 2017;8:28575-87. [PMID: 28212573 DOI: 10.18632/oncotarget.15338] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 28.7] [Reference Citation Analysis]
176 Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19:5003-5015. [PMID: 23881923 DOI: 10.1158/1078-0432.ccr-13-1391] [Cited by in Crossref: 281] [Cited by in F6Publishing: 157] [Article Influence: 35.1] [Reference Citation Analysis]
177 Gallyas F Jr, Sumegi B, Szabo C. Role of Akt Activation in PARP Inhibitor Resistance in Cancer. Cancers (Basel). 2020;12:532. [PMID: 32106627 DOI: 10.3390/cancers12030532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
178 Parsels LA, Karnak D, Parsels JD, Zhang Q, Vélez-Padilla J, Reichert ZR, Wahl DR, Maybaum J, O'Connor MJ, Lawrence TS, Morgan MA. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Mol Cancer Res 2018;16:222-32. [PMID: 29133592 DOI: 10.1158/1541-7786.MCR-17-0455] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 14.3] [Reference Citation Analysis]
179 Prasad R, Horton JK, Wilson SH. Requirements for PARP-1 covalent crosslinking to DNA (PARP-1 DPC). DNA Repair (Amst) 2020;90:102850. [PMID: 32438305 DOI: 10.1016/j.dnarep.2020.102850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
180 Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer. 2016;15:359-366. [PMID: 26873719 DOI: 10.1007/s10689-016-9883-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
181 Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50. [PMID: 25366685 DOI: 10.1200/JCO.2014.56.2728] [Cited by in Crossref: 1000] [Cited by in F6Publishing: 501] [Article Influence: 142.9] [Reference Citation Analysis]
182 Pommier Y, Huang SY, Gao R, Das BB, Murai J, Marchand C. Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair (Amst). 2014;19:114-129. [PMID: 24856239 DOI: 10.1016/j.dnarep.2014.03.020] [Cited by in Crossref: 174] [Cited by in F6Publishing: 150] [Article Influence: 24.9] [Reference Citation Analysis]
183 Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP. Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells. Front Oncol 2021;11:694793. [PMID: 34367977 DOI: 10.3389/fonc.2021.694793] [Reference Citation Analysis]
184 Keung MYT, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med 2019;8:E435. [PMID: 30934991 DOI: 10.3390/jcm8040435] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
185 Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM, Wang HG, De S, Moldovan GL. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nat Commun 2020;11:6118. [PMID: 33257658 DOI: 10.1038/s41467-020-19961-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
186 Das BB, Huang SY, Murai J, Rehman I, Amé JC, Sengupta S, Das SK, Majumdar P, Zhang H, Biard D, Majumder HK, Schreiber V, Pommier Y. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 2014;42:4435-49. [PMID: 24493735 DOI: 10.1093/nar/gku088] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 16.7] [Reference Citation Analysis]
187 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
188 Prasad R, Horton JK, Dai DP, Wilson SH. Repair pathway for PARP-1 DNA-protein crosslinks. DNA Repair (Amst) 2019;73:71-7. [PMID: 30466837 DOI: 10.1016/j.dnarep.2018.11.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
189 Reilly SW, Puentes LN, Wilson K, Hsieh CJ, Weng CC, Makvandi M, Mach RH. Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity. J Med Chem 2018;61:5367-79. [PMID: 29856625 DOI: 10.1021/acs.jmedchem.8b00576] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
190 Dok R, Bamps M, Glorieux M, Zhao P, Sablina A, Nuyts S. Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas. Int J Cancer 2020;146:1075-85. [PMID: 31283004 DOI: 10.1002/ijc.32558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
191 Zhao L, Si CS, Yu Y, Lu JW, Zhuang Y. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51. Cancer Sci 2019;110:3543-52. [PMID: 31541611 DOI: 10.1111/cas.14201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
192 Zhao H, Thienpont B, Yesilyurt BT, Moisse M, Reumers J, Coenegrachts L, Sagaert X, Schrauwen S, Smeets D, Matthijs G, Aerts S, Cools J, Metcalf A, Spurdle A, Amant F, Lambrechts D; ANECS. Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. Elife 2014;3:e02725. [PMID: 25085081 DOI: 10.7554/eLife.02725] [Cited by in Crossref: 46] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
193 Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW. ARe we there yet? Understanding androgen receptor signaling in breast cancer. NPJ Breast Cancer 2020;6:47. [PMID: 33062889 DOI: 10.1038/s41523-020-00190-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
194 Prasad R, Horton JK, Chastain PD 2nd, Gassman NR, Freudenthal BD, Hou EW, Wilson SH. Suicidal cross-linking of PARP-1 to AP site intermediates in cells undergoing base excision repair. Nucleic Acids Res 2014;42:6337-51. [PMID: 24771347 DOI: 10.1093/nar/gku288] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
195 Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, Pascal JM. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res 2014;74:31-7. [PMID: 24189460 DOI: 10.1158/0008-5472.CAN-13-1701] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
196 Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res 2017;19:107. [PMID: 28893315 DOI: 10.1186/s13058-017-0896-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
197 Peyraud F, Italiano A. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers (Basel) 2020;12:E1502. [PMID: 32526888 DOI: 10.3390/cancers12061502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 31.0] [Reference Citation Analysis]
198 Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP Inhibitors in Breast Cancer. Curr Treat Options Oncol 2018;19:21. [PMID: 29644491 DOI: 10.1007/s11864-018-0540-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
199 Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 2021. [PMID: 34285417 DOI: 10.1038/s41571-021-00532-x] [Reference Citation Analysis]
200 Cseh AM, Fábián Z, Sümegi B, Scorrano L. Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. Oncotarget 2017;8:50221-39. [PMID: 28430591 DOI: 10.18632/oncotarget.16859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
201 Yan C, Brunson DC, Tang Q, Do D, Iftimia NA, Moore JC, Hayes MN, Welker AM, Garcia EG, Dubash TD, Hong X, Drapkin BJ, Myers DT, Phat S, Volorio A, Marvin DL, Ligorio M, Dershowitz L, McCarthy KM, Karabacak MN, Fletcher JA, Sgroi DC, Iafrate JA, Maheswaran S, Dyson NJ, Haber DA, Rawls JF, Langenau DM. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell 2019;177:1903-1914.e14. [PMID: 31031007 DOI: 10.1016/j.cell.2019.04.004] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 42.0] [Reference Citation Analysis]
202 Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nat Commun. 2017;8:15981. [PMID: 28714471 DOI: 10.1038/ncomms15981] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
203 Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 2016;3:3. [PMID: 27231574 DOI: 10.1186/s40661-016-0024-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
204 Bridges KA, Toniatti C, Buser CA, Liu H, Buchholz TA, Meyn RE. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget 2014;5:5076-86. [PMID: 24970803 DOI: 10.18632/oncotarget.2083] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
205 Engbrecht M, Mangerich A. The Nucleolus and PARP1 in Cancer Biology. Cancers (Basel) 2020;12:E1813. [PMID: 32640701 DOI: 10.3390/cancers12071813] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
206 Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of PARPs. Front Oncol 2013;3:301. [PMID: 24392349 DOI: 10.3389/fonc.2013.00301] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 10.4] [Reference Citation Analysis]
207 Pellegrino B, Mateo J, Serra V, Balmaña J. Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? ESMO Open 2019;4:e000480. [PMID: 31231558 DOI: 10.1136/esmoopen-2018-000480] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
208 Margulies CM, Chaim IA, Mazumder A, Criscione J, Samson LD. Alkylation induced cerebellar degeneration dependent on Aag and Parp1 does not occur via previously established cell death mechanisms. PLoS One 2017;12:e0184619. [PMID: 28886188 DOI: 10.1371/journal.pone.0184619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
209 Roberts CM, Cardenas C, Tedja R. The Role of Intra-Tumoral Heterogeneity and Its Clinical Relevance in Epithelial Ovarian Cancer Recurrence and Metastasis. Cancers (Basel) 2019;11:E1083. [PMID: 31366178 DOI: 10.3390/cancers11081083] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
210 Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. J Oncol 2020;2020:4986365. [PMID: 32963528 DOI: 10.1155/2020/4986365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
211 Sugino K, Tamura R, Nakaoka H, Yachida N, Yamaguchi M, Mori Y, Yamawaki K, Suda K, Ishiguro T, Adachi S, Isobe M, Yamaguchi M, Kashima K, Motoyama T, Inoue I, Yoshihara K, Enomoto T. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Sci Rep 2019;9:17808. [PMID: 31780705 DOI: 10.1038/s41598-019-54116-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
212 Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med 2016;20:581-93. [PMID: 26800494 DOI: 10.1111/jcmm.12771] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
213 Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S. Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. Int J Nanomedicine 2018;13:8063-74. [PMID: 30555227 DOI: 10.2147/IJN.S186881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
214 Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF. Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition. Radiat Res 2016;186:327-32. [PMID: 27588595 DOI: 10.1667/RR14437.1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
215 Leichman L, Groshen S, O’Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist. 2016;21:172-177. [PMID: 26786262 DOI: 10.1634/theoncologist.2015-0319] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
216 Rahman MM, Mohiuddin M, Shamima Keka I, Yamada K, Tsuda M, Sasanuma H, Andreani J, Guerois R, Borde V, Charbonnier JB, Takeda S. Genetic evidence for the involvement of mismatch repair proteins, PMS2 and MLH3, in a late step of homologous recombination. J Biol Chem 2020;295:17460-75. [PMID: 33453991 DOI: 10.1074/jbc.RA120.013521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
217 Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S. The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. Oncol Res 2017;25:1441-51. [PMID: 28429680 DOI: 10.3727/096504017X14926854178616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017;3:49. [PMID: 29238749 DOI: 10.1038/s41523-017-0052-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
219 Zhou P, Wang J, Mishail D, Wang CY. Recent advancements in PARP inhibitors-based targeted cancer therapy. Precis Clin Med. 2020;3:187-201. [PMID: 32983586 DOI: 10.1093/pcmedi/pbaa030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
220 Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC. CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Front Oncol 2015;5:123. [PMID: 26082895 DOI: 10.3389/fonc.2015.00123] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
221 Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, Kim RK, Bloomstein JD, Xiao Y, Bacal J, Saldivar JC, Le QT, Cimprich KA, Rankin EB, Giaccia AJ. Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. J Clin Invest 2021;131:146256. [PMID: 34060485 DOI: 10.1172/JCI146256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Genois MM, Gagné JP, Yasuhara T, Jackson J, Saxena S, Langelier MF, Ahel I, Bedford MT, Pascal JM, Vindigni A, Poirier GG, Zou L. CARM1 regulates replication fork speed and stress response by stimulating PARP1. Mol Cell 2021;81:784-800.e8. [PMID: 33412112 DOI: 10.1016/j.molcel.2020.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
223 Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One 2013;8:e61520. [PMID: 23634208 DOI: 10.1371/journal.pone.0061520] [Cited by in Crossref: 114] [Cited by in F6Publishing: 98] [Article Influence: 14.3] [Reference Citation Analysis]
224 Schoonen PM, Kok YP, Wierenga E, Bakker B, Foijer F, Spierings DCJ, van Vugt MATM. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. Mol Oncol 2019;13:2422-40. [PMID: 31529615 DOI: 10.1002/1878-0261.12573] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
225 Musacchio L, Caruso G, Pisano C, Cecere SC, Di Napoli M, Attademo L, Tambaro R, Russo D, Califano D, Palaia I, Muzii L, Benedetti Panici P, Pignata S. PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives. Cancer Manag Res 2020;12:6123-35. [PMID: 32801862 DOI: 10.2147/CMAR.S221001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
226 Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B, Vizza E. Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg 2020;9:1149-63. [PMID: 32953630 DOI: 10.21037/gs-20-413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
227 Criscuolo D, Morra F, Giannella R, Visconti R, Cerrato A, Celetti A. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. J Exp Clin Cancer Res 2019;38:91. [PMID: 30791940 DOI: 10.1186/s13046-019-1089-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
228 Antolín AA, Mestres J. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget 2014;5:3023-8. [PMID: 24632590 DOI: 10.18632/oncotarget.1814] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
229 Hoffman J, Chakrabarti J, Plotka A, Milillo Naraine A, Kanamori D, Moroose R, Nguyen L, Wang D, Wainberg ZA. Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors. Anticancer Drugs 2019;30:523-32. [PMID: 30875341 DOI: 10.1097/CAD.0000000000000772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
230 Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 2019;8:29. [PMID: 31737426 DOI: 10.1186/s40164-019-0154-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
231 Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR. Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Res 2017;77:5011-25. [PMID: 28687616 DOI: 10.1158/0008-5472.CAN-16-2704] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
232 de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer 2019;19:901. [PMID: 31500595 DOI: 10.1186/s12885-019-6121-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
233 Kohl V, Flach J, Naumann N, Brendel S, Kleiner H, Weiss C, Seifarth W, Nowak D, Hofmann WK, Fabarius A, Popp HD. Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. Cancers (Basel) 2019;11:E1493. [PMID: 31623402 DOI: 10.3390/cancers11101493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
234 Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer 2021;2:66-82. [PMID: 33738458 DOI: 10.1038/s43018-020-00148-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
235 Nishihara K, Huang R, Zhao J, Shahane SA, Witt KL, Smith-Roe SL, Tice RR, Takeda S, Xia M. Identification of genotoxic compounds using isogenic DNA repair deficient DT40 cell lines on a quantitative high throughput screening platform. Mutagenesis 2016;31:69-81. [PMID: 26243743 DOI: 10.1093/mutage/gev055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
236 Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, Choi EY, McLaughlin L, Kogan AA, Xia L, Lapidus R, Mahmood J, Baylin SB, Rassool FV. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation. Proc Natl Acad Sci U S A 2019;116:22609-18. [PMID: 31591209 DOI: 10.1073/pnas.1903765116] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
237 Desai D, Khandwala P, Parsi M, Potdar R. PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer. Med Oncol 2021;38:61. [PMID: 33891252 DOI: 10.1007/s12032-021-01507-9] [Reference Citation Analysis]
238 Allgayer J, Kitsera N, Bartelt S, Epe B, Khobta A. Widespread transcriptional gene inactivation initiated by a repair intermediate of 8-oxoguanine. Nucleic Acids Res 2016;44:7267-80. [PMID: 27220469 DOI: 10.1093/nar/gkw473] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
239 Southgate HED, Chen L, Tweddle DA, Curtin NJ. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers (Basel) 2020;12:E1095. [PMID: 32354033 DOI: 10.3390/cancers12051095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
240 van de Ven AL, Tangutoori S, Baldwin P, Qiao J, Gharagouzloo C, Seitzer N, Clohessy JG, Makrigiorgos GM, Cormack R, Pandolfi PP, Sridhar S. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Mol Cancer Ther 2017;16:1279-89. [PMID: 28500233 DOI: 10.1158/1535-7163.MCT-16-0740] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
241 Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, Olsen E, Thomas DG, Zhang A, Hirsh N, Ritter CL, Liu M, Nyati S, Pierce LJ, Jagsi R, Speers C. PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. Mol Cancer Ther 2019;18:2063-73. [PMID: 31413177 DOI: 10.1158/1535-7163.MCT-19-0520] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
242 Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 2017;16:2735-46. [PMID: 28947502 DOI: 10.1158/1535-7163.MCT-17-0365] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 6.8] [Reference Citation Analysis]
243 Srinivasan G, Williamson EA, Kong K, Jaiswal AS, Huang G, Kim HS, Schärer O, Zhao W, Burma S, Sung P, Hromas R. MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers. Proc Natl Acad Sci U S A 2019;116:17438-43. [PMID: 31395736 DOI: 10.1073/pnas.1903150116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
244 Prasanna T, Wu F, Khanna KK, Yip D, Malik L, Dahlstrom JE, Rao S. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy. Cancer Sci 2018;109:3383-92. [PMID: 30230653 DOI: 10.1111/cas.13799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
245 Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1. J Exp Clin Cancer Res 2020;39:3. [PMID: 31898520 DOI: 10.1186/s13046-019-1490-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
246 Farhy C, Hariharan S, Ylanko J, Orozco L, Zeng FY, Pass I, Ugarte F, Forsberg EC, Huang CT, Andrews DW, Terskikh AV. Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape. Elife 2019;8:e49683. [PMID: 31637999 DOI: 10.7554/eLife.49683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
247 Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol 2017;9:253-67. [PMID: 28491146 DOI: 10.1177/1758834016687254] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 13.8] [Reference Citation Analysis]
248 Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, Gaillard S, Ayhan A, Viswanathan A, Seidman MM, Franco S, Leung AKL, Bohr VA, Shih IM, Wang TL. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. Clin Cancer Res 2019;25:5584-94. [PMID: 31196855 DOI: 10.1158/1078-0432.CCR-18-4222] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 17.5] [Reference Citation Analysis]
249 Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene 2018;37:6463-76. [PMID: 30076413 DOI: 10.1038/s41388-018-0424-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
250 Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 2020;38:388-94. [PMID: 31461380 DOI: 10.1200/JCO.19.01304] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
251 Eustermann S, Wu WF, Langelier MF, Yang JC, Easton LE, Riccio AA, Pascal JM, Neuhaus D. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1. Mol Cell 2015;60:742-54. [PMID: 26626479 DOI: 10.1016/j.molcel.2015.10.032] [Cited by in Crossref: 139] [Cited by in F6Publishing: 127] [Article Influence: 23.2] [Reference Citation Analysis]
252 Jette NR, Radhamani S, Arthur G, Ye R, Goutam S, Bolyos A, Petersen LF, Bose P, Bebb DG, Lees-Miller SP. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells. Br J Cancer 2019;121:600-10. [PMID: 31481733 DOI: 10.1038/s41416-019-0565-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
253 Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res 2015;21:4184-93. [PMID: 25779942 DOI: 10.1158/1078-0432.CCR-14-2112] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
254 Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, Sinno V, Ronzulli D, Giolitto S, de Braud F. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Target Oncol 2021;16:59-68. [PMID: 33369704 DOI: 10.1007/s11523-020-00780-4] [Reference Citation Analysis]
255 Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J Cancer 2019;120:279-85. [PMID: 30655615 DOI: 10.1038/s41416-018-0349-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
256 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. [PMID: 28302823 DOI: 10.1126/science.aam7344] [Cited by in Crossref: 882] [Cited by in F6Publishing: 729] [Article Influence: 220.5] [Reference Citation Analysis]
257 Kim C, Chen C, Yu Y. Avoid the trap: Targeting PARP1 beyond human malignancy. Cell Chem Biol 2021;28:456-62. [PMID: 33657415 DOI: 10.1016/j.chembiol.2021.02.004] [Reference Citation Analysis]
258 Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437-47. [PMID: 31218365 DOI: 10.1093/annonc/mdz192] [Cited by in Crossref: 135] [Cited by in F6Publishing: 113] [Article Influence: 135.0] [Reference Citation Analysis]
259 Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014;13:433-43. [PMID: 24356813 DOI: 10.1158/1535-7163.MCT-13-0803] [Cited by in Crossref: 379] [Cited by in F6Publishing: 207] [Article Influence: 47.4] [Reference Citation Analysis]
260 Kumari A, Iwasaki T, Pyndiah S, Cassimere EK, Palani CD, Sakamuro D. Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation. Cell Death Differ 2015;22:311-22. [PMID: 25257171 DOI: 10.1038/cdd.2014.146] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
261 Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res 2015;21:1574-82. [PMID: 25589624 DOI: 10.1158/1078-0432.CCR-14-2565] [Cited by in Crossref: 80] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
262 Shao Z, Lee BJ, Rouleau-Turcotte É, Langelier MF, Lin X, Estes VM, Pascal JM, Zha S. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo. Nucleic Acids Res 2020;48:9694-709. [PMID: 32890402 DOI: 10.1093/nar/gkaa718] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
263 Kohn EC, Lee JM, Ivy SP. The HRD Decision-Which PARP Inhibitor to Use for Whom and When. Clin Cancer Res 2017;23:7155-7. [PMID: 28974545 DOI: 10.1158/1078-0432.CCR-17-2186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
264 Rodell CB, Baldwin P, Fernandez B, Weissleder R, Sridhar S, Dubach JM. Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating in vitro and in vivo Encapsulated Drug Delivery. Adv Ther (Weinh) 2021;4:2000125. [PMID: 33997266 DOI: 10.1002/adtp.202000125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
265 Sorrells S, McKinnon KE, McBratney A, Sumey C. Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse. NPJ Genom Med 2021;6:17. [PMID: 33619265 DOI: 10.1038/s41525-021-00181-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 2016;7:76534-50. [PMID: 27708213 DOI: 10.18632/oncotarget.12266] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 40.7] [Reference Citation Analysis]
267 Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics 2017;7:4340-9. [PMID: 29158830 DOI: 10.7150/thno.18563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
268 Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014;74:287-97. [PMID: 24240700 DOI: 10.1158/0008-5472.CAN-13-2541] [Cited by in Crossref: 188] [Cited by in F6Publishing: 116] [Article Influence: 23.5] [Reference Citation Analysis]
269 Hassan S, Esch A, Liby T, Gray JW, Heiser LM. Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther 2017;16:2892-901. [PMID: 28958991 DOI: 10.1158/1535-7163.MCT-17-0170] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
270 Maede Y, Shimizu H, Fukushima T, Kogame T, Nakamura T, Miki T, Takeda S, Pommier Y, Murai J. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol Cancer Ther. 2014;13:214-220. [PMID: 24130054 DOI: 10.1158/1535-7163.MCT-13-0551] [Cited by in Crossref: 87] [Cited by in F6Publishing: 54] [Article Influence: 10.9] [Reference Citation Analysis]
271 Pazzaglia S, Pioli C. Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases. Cells 2019;9:E41. [PMID: 31877876 DOI: 10.3390/cells9010041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 18.0] [Reference Citation Analysis]
272 Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19:1381-8. [PMID: 24202391 DOI: 10.1038/nm.3369] [Cited by in Crossref: 269] [Cited by in F6Publishing: 234] [Article Influence: 33.6] [Reference Citation Analysis]
273 Kassab MA, Yu LL, Yu X. Targeting dePARylation for cancer therapy. Cell Biosci 2020;10:7. [PMID: 32010441 DOI: 10.1186/s13578-020-0375-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
274 Prasad CB, Prasad SB, Yadav SS, Pandey LK, Singh S, Pradhan S, Narayan G. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep 2017;7:12876. [PMID: 28993682 DOI: 10.1038/s41598-017-13232-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
275 Xia M, Guo Z, Hu Z. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials. Biomolecules 2021;11:722. [PMID: 34066020 DOI: 10.3390/biom11050722] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Fang P, Madden JA, Neums L, Moulder RK, Forrest ML, Chien J. Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition. Mol Cancer Res 2018;16:961-73. [PMID: 29545475 DOI: 10.1158/1541-7786.MCR-17-0607] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
277 Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G. PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. Front Oncol 2013;3:279. [PMID: 24294592 DOI: 10.3389/fonc.2013.00279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
278 Kim JW, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ. TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. Cancers (Basel) 2020;12:E334. [PMID: 32028591 DOI: 10.3390/cancers12020334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
279 Prokhorova E, Zobel F, Smith R, Zentout S, Gibbs-Seymour I, Schützenhofer K, Peters A, Groslambert J, Zorzini V, Agnew T, Brognard J, Nielsen ML, Ahel D, Huet S, Suskiewicz MJ, Ahel I. Serine-linked PARP1 auto-modification controls PARP inhibitor response. Nat Commun 2021;12:4055. [PMID: 34210965 DOI: 10.1038/s41467-021-24361-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
280 Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res 2014;74:2835-45. [PMID: 24662920 DOI: 10.1158/0008-5472.CAN-13-3229] [Cited by in Crossref: 83] [Cited by in F6Publishing: 49] [Article Influence: 11.9] [Reference Citation Analysis]
281 Lemech CR, Williams R, Thompson SR, McCaughan B, Chin M. Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report. BMC Res Notes 2016;9:386. [PMID: 27488020 DOI: 10.1186/s13104-016-2189-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
282 Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S. BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. JNCI Cancer Spectr 2020;4:pkz100. [PMID: 32175521 DOI: 10.1093/jncics/pkz100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, Hess AD, Smith BD, Karp JE, Kaufmann SH. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem 2014;289:20543-58. [PMID: 24895135 DOI: 10.1074/jbc.M114.549220] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
284 Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res 2017;23:697-706. [PMID: 27503200 DOI: 10.1158/1078-0432.CCR-16-0984] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
285 Huang Y, Li W, Yan W, Wu J, Chen L, Yao X, Gu F, Lv L, Zhao J, Zhao M, Xia T, Han Q, Li T, Ying X, Li T, Xia Q, Li A, Zhang X, Chen Y, Zhou T. Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer. Cell Death Dis 2019;10:428. [PMID: 31160555 DOI: 10.1038/s41419-019-1662-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
286 Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer 2017;116:884-92. [PMID: 28222073 DOI: 10.1038/bjc.2017.36] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
287 Jegadesan NK, Branzei D. DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects. Proc Natl Acad Sci U S A 2021;118:e2024258118. [PMID: 33879618 DOI: 10.1073/pnas.2024258118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer 2016;16:725. [PMID: 27613518 DOI: 10.1186/s12885-016-2754-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
289 Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget 2015;6:35542-55. [PMID: 26325261 DOI: 10.18632/oncotarget.4689] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
290 Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol 2021;14:51. [PMID: 33781305 DOI: 10.1186/s13045-021-01061-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
291 Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol 2020;8:564601. [PMID: 33015058 DOI: 10.3389/fcell.2020.564601] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 29.0] [Reference Citation Analysis]
292 Chowdhuri SP, Das BB. Top1-PARP1 association and beyond: from DNA topology to break repair. NAR Cancer 2021;3:zcab003. [PMID: 33981998 DOI: 10.1093/narcan/zcab003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98. [PMID: 31521196 DOI: 10.1186/s13045-019-0784-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 21.5] [Reference Citation Analysis]
294 Slade D. Mitotic functions of poly(ADP-ribose) polymerases. Biochem Pharmacol. 2019;167:33-43. [PMID: 30910692 DOI: 10.1016/j.bcp.2019.03.028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
295 Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma. Oncogene 2017;36:4682-91. [PMID: 28394338 DOI: 10.1038/onc.2017.40] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 12.5] [Reference Citation Analysis]
296 Haikarainen T, Schlesinger M, Obaji E, Fernández Villamil SH, Lehtiö L. Structural and Biochemical Characterization of Poly-ADP-ribose Polymerase from Trypanosoma brucei. Sci Rep 2017;7:3642. [PMID: 28623292 DOI: 10.1038/s41598-017-03751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. Int J Mol Sci 2019;20:E3100. [PMID: 31242618 DOI: 10.3390/ijms20123100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
298 Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol 2015;7:68-84. [PMID: 25755680 DOI: 10.1177/1758834014564775] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 14.3] [Reference Citation Analysis]
299 Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 2017;9:eaal1645. [PMID: 28747513 DOI: 10.1126/scitranslmed.aal1645] [Cited by in Crossref: 96] [Cited by in F6Publishing: 87] [Article Influence: 32.0] [Reference Citation Analysis]
300 Sander Effron S, Makvandi M, Lin L, Xu K, Li S, Lee H, Hou C, Pryma DA, Koch C, Mach RH. PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy. Cancer Biother Radiopharm 2017;32:9-15. [PMID: 28118040 DOI: 10.1089/cbr.2016.2133] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
301 Liu X, Liu T, Shang Y, Dai P, Zhang W, Lee BJ, Huang M, Yang D, Wu Q, Liu LD, Zheng X, Zhou BO, Dong J, Yeap LS, Hu J, Xiao T, Zha S, Casellas R, Liu XS, Meng FL. ERCC6L2 promotes DNA orientation-specific recombination in mammalian cells. Cell Res 2020;30:732-44. [PMID: 32355287 DOI: 10.1038/s41422-020-0328-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
302 Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, Zou L. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 2017;31:318-32. [PMID: 28242626 DOI: 10.1101/gad.290957.116] [Cited by in Crossref: 167] [Cited by in F6Publishing: 141] [Article Influence: 41.8] [Reference Citation Analysis]
303 De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol 2013;3:228. [PMID: 24062981 DOI: 10.3389/fonc.2013.00228] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
304 Demin AA, Hirota K, Tsuda M, Adamowicz M, Hailstone R, Brazina J, Gittens W, Kalasova I, Shao Z, Zha S, Sasanuma H, Hanzlikova H, Takeda S, Caldecott KW. XRCC1 prevents toxic PARP1 trapping during DNA base excision repair. Mol Cell 2021;81:3018-3030.e5. [PMID: 34102106 DOI: 10.1016/j.molcel.2021.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Murai J. Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int J Clin Oncol 2017;22:619-28. [PMID: 28643177 DOI: 10.1007/s10147-017-1145-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
306 Li M, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell. 2013;23:693-704. [PMID: 23680151 DOI: 10.1016/j.ccr.2013.03.025] [Cited by in Crossref: 186] [Cited by in F6Publishing: 156] [Article Influence: 23.3] [Reference Citation Analysis]
307 Klein FG, Granier C, Zhao Y, Pan Q, Tong Z, Gschwend JE, Holm PS, Nawroth R. Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer. J Pers Med 2021;11:340. [PMID: 33923231 DOI: 10.3390/jpm11050340] [Reference Citation Analysis]
308 Bilokapic S, Suskiewicz MJ, Ahel I, Halic M. Bridging of DNA breaks activates PARP2-HPF1 to modify chromatin. Nature 2020;585:609-13. [PMID: 32939087 DOI: 10.1038/s41586-020-2725-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
309 Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 2018;559:285-9. [PMID: 29973717 DOI: 10.1038/s41586-018-0291-z] [Cited by in Crossref: 147] [Cited by in F6Publishing: 110] [Article Influence: 49.0] [Reference Citation Analysis]
310 Park SH, Jang KY, Kim MJ, Yoon S, Jo Y, Kwon SM, Kim KM, Kwon KS, Kim CY, Woo HG. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications. Oncotarget 2015;6:44819-31. [PMID: 26540566 DOI: 10.18632/oncotarget.6264] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
311 Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDevitt MA, Kaufmann SH. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clin Cancer Res 2016;22:3894-902. [PMID: 26979391 DOI: 10.1158/1078-0432.CCR-15-2351] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
312 Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, Hewitt G, Patel H, Goldstone R, Carell T, Boulton SJ, MacRae J, Taylor IA, West SC. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 2021;372:156-65. [PMID: 33833118 DOI: 10.1126/science.abb4542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
313 Aleksandrov R, Hristova R, Stoynov S, Gospodinov A. The Chromatin Response to Double-Strand DNA Breaks and Their Repair. Cells 2020;9:E1853. [PMID: 32784607 DOI: 10.3390/cells9081853] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
314 Lester A, Rapkins R, Nixdorf S, Khasraw M, McDonald K. Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? Clin Transl Oncol 2017;19:273-8. [PMID: 27655368 DOI: 10.1007/s12094-016-1547-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
315 Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med 2019;11:e9982. [PMID: 31273933 DOI: 10.15252/emmm.201809982] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
316 Chen YX, Tan LM, Gong JP, Huang MS, Yin JY, Zhang W, Zhou HH, Liu ZQ. Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer. Acta Pharmacol Sin 2021. [PMID: 33589795 DOI: 10.1038/s41401-020-00604-1] [Reference Citation Analysis]
317 Carlucci G, Carney B, Brand C, Kossatz S, Irwin CP, Carlin SD, Keliher EJ, Weber W, Reiner T. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Mol Imaging Biol 2015;17:848-55. [PMID: 25895168 DOI: 10.1007/s11307-015-0858-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
318 Hegedűs C, Boros G, Fidrus E, Kis GN, Antal M, Juhász T, Janka EA, Jankó L, Paragh G, Emri G, Bai P, Remenyik É. PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes-Implications for UV-Induced DNA Repair and Photocarcinogenesis. Cancers (Basel) 2019;12:E5. [PMID: 31861350 DOI: 10.3390/cancers12010005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
319 Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) 2017;9:E109. [PMID: 28829366 DOI: 10.3390/cancers9080109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
320 Gui B, Gui F, Takai T, Feng C, Bai X, Fazli L, Dong X, Liu S, Zhang X, Zhang W, Kibel AS, Jia L. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc Natl Acad Sci U S A 2019;116:14573-82. [PMID: 31266892 DOI: 10.1073/pnas.1908547116] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
321 Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca". Diagnostics (Basel) 2019;9:E55. [PMID: 31109041 DOI: 10.3390/diagnostics9020055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
322 Adashek JJ, Jain RK, Zhang J. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. Cells 2019;8:E860. [PMID: 31404966 DOI: 10.3390/cells8080860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
323 Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM. Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. PLoS One 2017;12:e0171582. [PMID: 28158293 DOI: 10.1371/journal.pone.0171582] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
324 Feng FY, de Bono JS, Rubin MA, Knudsen KE. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell 2015;58:925-34. [PMID: 26091341 DOI: 10.1016/j.molcel.2015.04.016] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 15.5] [Reference Citation Analysis]
325 Patel MR, Bhatt A, Steffen JD, Chergui A, Murai J, Pommier Y, Pascal JM, Trombetta LD, Fronczek FR, Talele TT. Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors. J Med Chem 2014;57:5579-601. [PMID: 24922587 DOI: 10.1021/jm5002502] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
326 Tao M, Cheng J, Wu X. Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review. Onco Targets Ther 2020;13:12979-86. [PMID: 33376347 DOI: 10.2147/OTT.S281302] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Keung MY, Wu Y, Badar F, Vadgama JV. Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. J Clin Med 2020;9:E940. [PMID: 32235451 DOI: 10.3390/jcm9040940] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
328 Komulainen E, Badman J, Rey S, Rulten S, Ju L, Fennell K, Kalasova I, Ilievova K, McKinnon PJ, Hanzlikova H, Staras K, Caldecott KW. Parp1 hyperactivity couples DNA breaks to aberrant neuronal calcium signalling and lethal seizures. EMBO Rep 2021;22:e51851. [PMID: 33932076 DOI: 10.15252/embr.202051851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Wagner LM. Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther 2015;8:1931-9. [PMID: 26251615 DOI: 10.2147/OTT.S69935] [Cited by in Crossref: 50] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
330 Min A, Im SA. PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. Cancers (Basel) 2020;12:E394. [PMID: 32046300 DOI: 10.3390/cancers12020394] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 33.0] [Reference Citation Analysis]
331 Howes TRL, Sallmyr A, Brooks R, Greco GE, Jones DE, Matsumoto Y, Tomkinson AE. Structure-activity relationships among DNA ligase inhibitors: Characterization of a selective uncompetitive DNA ligase I inhibitor. DNA Repair (Amst) 2017;60:29-39. [PMID: 29078112 DOI: 10.1016/j.dnarep.2017.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
332 Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP Inhibition in Cancer: An Update on Clinical Development. Target Oncol 2019;14:657-79. [PMID: 31625002 DOI: 10.1007/s11523-019-00680-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 37.0] [Reference Citation Analysis]
333 Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep 2019;9:1853. [PMID: 30755715 DOI: 10.1038/s41598-019-38534-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 39.0] [Reference Citation Analysis]
334 Roidos P, Sungalee S, Benfatto S, Serçin Ö, Stütz AM, Abdollahi A, Mauer J, Zenke FT, Korbel JO, Mardin BR. A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice. Nat Commun 2020;11:4077. [PMID: 32796846 DOI: 10.1038/s41467-020-17962-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
335 Lee SG, Kim N, Kim SM, Park IB, Kim H, Kim S, Kim BG, Hwang JM, Baek IJ, Gartner A, Park JH, Myung K. Ewing sarcoma protein promotes dissociation of poly(ADP-ribose) polymerase 1 from chromatin. EMBO Rep 2020;21:e48676. [PMID: 33006225 DOI: 10.15252/embr.201948676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
336 Quaas A, Waldschmidt D, Alakus H, Zander T, Heydt C, Goeser T, Daheim M, Kasper P, Plum P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Göbel H, Tharun L, Buettner R, Merkelbach-Bruse S. Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel. BMC Gastroenterol 2018;18:75. [PMID: 29855275 DOI: 10.1186/s12876-018-0803-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
337 Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what's new? Future Oncol 2014;10:1215-37. [PMID: 24947262 DOI: 10.2217/fon.14.60] [Cited by in Crossref: 104] [Cited by in F6Publishing: 89] [Article Influence: 17.3] [Reference Citation Analysis]
338 Duan W, Gao L, Aguila B, Kalvala A, Otterson GA, Villalona-Calero MA. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol 2014;4:368. [PMID: 25566506 DOI: 10.3389/fonc.2014.00368] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
339 Langelier MF, Zandarashvili L, Aguiar PM, Black BE, Pascal JM. NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains. Nat Commun 2018;9:844. [PMID: 29487285 DOI: 10.1038/s41467-018-03234-8] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 27.7] [Reference Citation Analysis]
340 Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nat Commun 2018;9:176. [PMID: 29330466 DOI: 10.1038/s41467-017-02096-w] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 14.7] [Reference Citation Analysis]
341 Wilson TC, Xavier MA, Knight J, Verhoog S, Torres JB, Mosley M, Hopkins SL, Wallington S, Allen PD, Kersemans V, Hueting R, Smart S, Gouverneur V, Cornelissen B. PET Imaging of PARP Expression Using 18F-Olaparib. J Nucl Med 2019;60:504-10. [PMID: 30389822 DOI: 10.2967/jnumed.118.213223] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 10.7] [Reference Citation Analysis]
342 McCann KE, Hurvitz SA, McAndrew N. Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs 2019;79:1217-30. [PMID: 31254268 DOI: 10.1007/s40265-019-01155-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
343 Chang HR, Jung E, Cho S, Jeon YJ, Kim Y. Targeting Non-Oncogene Addiction for Cancer Therapy. Biomolecules 2021;11:129. [PMID: 33498235 DOI: 10.3390/biom11020129] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13. [PMID: 30672100 DOI: 10.1111/jcmm.14133] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
345 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
346 Kojima Y, Machida Y, Palani S, Caulfield TR, Radisky ES, Kaufmann SH, Machida YJ. FAM111A protects replication forks from protein obstacles via its trypsin-like domain. Nat Commun 2020;11:1318. [PMID: 32165630 DOI: 10.1038/s41467-020-15170-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
347 Gibson SJ, Tewari KS, Monk BJ, Chase DM. Updates on drug discovery in ovarian cancer. Gynecol Oncol Res Pract 2014;1:3. [PMID: 27231556 DOI: 10.1186/2053-6844-1-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
348 Morii I, Iwabuchi Y, Mori S, Suekuni M, Natsume T, Yoshida K, Sugimoto N, Kanemaki MT, Fujita M. Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib. Cancer Sci 2019;110:1044-53. [PMID: 30648820 DOI: 10.1111/cas.13941] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
349 Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci 2017;108:1834-42. [PMID: 28665051 DOI: 10.1111/cas.13307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
350 Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30:903-15. [PMID: 32276934 DOI: 10.1136/ijgc-2020-001288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
351 Thakar T, Moldovan GL. The emerging determinants of replication fork stability. Nucleic Acids Res 2021;49:7224-38. [PMID: 33978751 DOI: 10.1093/nar/gkab344] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol 2018;29:154-61. [PMID: 29045554 DOI: 10.1093/annonc/mdx505] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 47.5] [Reference Citation Analysis]
353 Jiang Y, Martin J, Alkadhimi M, Shigemori K, Kinchesh P, Gilchrist S, Kersemans V, Smart S, Thompson JM, Hill MA, O'Connor MJ, Davies BR, Ryan AJ. Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model. Br J Cancer 2021;124:1809-19. [PMID: 33742147 DOI: 10.1038/s41416-021-01296-y] [Reference Citation Analysis]
354 Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells. Mol Cancer Ther 2020;19:199-210. [PMID: 31534014 DOI: 10.1158/1535-7163.MCT-19-0242] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
355 Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG. New Approaches to SCLC Therapy: From the Laboratory to the Clinic. J Thorac Oncol 2020;15:520-40. [PMID: 32018053 DOI: 10.1016/j.jtho.2020.01.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
356 Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol 2019;11:1758835919849753. [PMID: 31205507 DOI: 10.1177/1758835919849753] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
357 Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014;5:5637-50. [PMID: 25026298 DOI: 10.18632/oncotarget.2154] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]
358 Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers (Basel) 2019;11:E352. [PMID: 30871108 DOI: 10.3390/cancers11030352] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 16.5] [Reference Citation Analysis]
359 Ashour ME, Mosammaparast N. Mechanisms of damage tolerance and repair during DNA replication. Nucleic Acids Res 2021;49:3033-47. [PMID: 33693881 DOI: 10.1093/nar/gkab101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Lee KH, Sohn J, Goodwin A, Usari T, Lanzalone S, Im SA, Kim SB. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. Cancer Res Treat 2021. [PMID: 33781053 DOI: 10.4143/crt.2020.1381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
361 Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist 2018;23:697-703. [PMID: 29593098 DOI: 10.1634/theoncologist.2017-0485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
362 van Wietmarschen N, Nussenzweig A. Mechanism for Synthetic Lethality in BRCA-Deficient Cancers: No Longer Lagging Behind. Mol Cell 2018;71:877-8. [PMID: 30241603 DOI: 10.1016/j.molcel.2018.08.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
363 Mello CA, Campos FAB, Santos TG, Silva MLG, Torrezan GT, Costa FD, Formiga MN, Nicolau U, Nascimento AG, Silva C, Curado MP, Nakagawa SA, Lopes A, Aguiar S Jr. Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging Therapy. Cancers (Basel) 2021;13:498. [PMID: 33525546 DOI: 10.3390/cancers13030498] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Peng B, Shi R, Bian J, Li Y, Wang P, Wang H, Liao J, Zhu WG, Xu X. PARP1 and CHK1 coordinate PLK1 enzymatic activity during the DNA damage response to promote homologous recombination-mediated repair. Nucleic Acids Res 2021;49:7554-70. [PMID: 34197606 DOI: 10.1093/nar/gkab584] [Reference Citation Analysis]
365 Soll JM, Sobol RW, Mosammaparast N. Regulation of DNA Alkylation Damage Repair: Lessons and Therapeutic Opportunities. Trends Biochem Sci. 2017;42:206-218. [PMID: 27816326 DOI: 10.1016/j.tibs.2016.10.001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
366 Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol 2017;13:307-20. [PMID: 27739325 DOI: 10.2217/fon-2016-0412] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
367 Barayan R, Ran X, Lok BH. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches. J Thorac Dis 2020;12:6240-52. [PMID: 33209463 DOI: 10.21037/jtd.2020.03.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
368 Póti Á, Berta K, Xiao Y, Pipek O, Klus GT, Ried T, Csabai I, Wilcoxen K, Mikule K, Szallasi Z, Szüts D. Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts. Br J Cancer 2018;119:1392-400. [PMID: 30425352 DOI: 10.1038/s41416-018-0312-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
369 Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther 2016;161:79-96. [PMID: 27000769 DOI: 10.1016/j.pharmthera.2016.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
370 Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell 2020;78:1070-85. [PMID: 32459988 DOI: 10.1016/j.molcel.2020.04.035] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 36.0] [Reference Citation Analysis]
371 Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene 2018;37:2793-805. [PMID: 29511347 DOI: 10.1038/s41388-018-0130-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
372 Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clin Cancer Res 2017;23:899-907. [PMID: 27551000 DOI: 10.1158/1078-0432.CCR-16-1274] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
373 Khadka P, Hsu JK, Veith S, Tadokoro T, Shamanna RA, Mangerich A, Croteau DL, Bohr VA. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities. Mol Cell Biol 2015;35:3974-89. [PMID: 26391948 DOI: 10.1128/MCB.00427-15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
374 Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers (Basel) 2020;12:E687. [PMID: 32183301 DOI: 10.3390/cancers12030687] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 31.0] [Reference Citation Analysis]
375 Coletti A, Greco FA, Dolciami D, Camaioni E, Sardella R, Pallotta MT, Volpi C, Orabona C, Grohmann U, Macchiarulo A. Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry. Medchemcomm 2017;8:1378-92. [PMID: 30108849 DOI: 10.1039/c7md00109f] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
376 Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel) 2018;10:E506. [PMID: 30544963 DOI: 10.3390/cancers10120506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
377 Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Clin Cancer Res 2018;24:3163-75. [PMID: 29615458 DOI: 10.1158/1078-0432.CCR-18-0204] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 16.3] [Reference Citation Analysis]
378 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
379 Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y. SLFN11 Blocks Stressed Replication Forks Independently of ATR. Mol Cell 2018;69:371-384.e6. [PMID: 29395061 DOI: 10.1016/j.molcel.2018.01.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 47.0] [Reference Citation Analysis]
380 Kwon M, Jang H, Kim EH, Roh JL. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions. Cell Cycle 2016;15:3105-14. [PMID: 27686740 DOI: 10.1080/15384101.2016.1235104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
381 Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer 2014;110:1977-84. [PMID: 24556618 DOI: 10.1038/bjc.2014.91] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
382 Koh JH, Kim JY. Role of PGC-1α in the Mitochondrial NAD+ Pool in Metabolic Diseases. Int J Mol Sci 2021;22:4558. [PMID: 33925372 DOI: 10.3390/ijms22094558] [Reference Citation Analysis]
383 Jachimowicz RD, Goergens J, Reinhardt HC. DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. Cell Cycle 2019;18:1423-34. [PMID: 31116084 DOI: 10.1080/15384101.2019.1618542] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
384 Tran Chau V, Liu W, Gerbé de Thoré M, Meziani L, Mondini M, O'Connor MJ, Deutsch E, Clémenson C. Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models. Br J Cancer 2020;123:762-71. [PMID: 32546832 DOI: 10.1038/s41416-020-0931-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
385 Colombo I, Lheureux S, Oza AM. Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Des Devel Ther. 2018;12:605-617. [PMID: 29606854 DOI: 10.2147/dddt.s130809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
386 Steffen JD, McCauley MM, Pascal JM. Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage. Nucleic Acids Res 2016;44:9771-83. [PMID: 27530425 DOI: 10.1093/nar/gkw710] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
387 Smith R, Sellou H, Chapuis C, Huet S, Timinszky G. CHD3 and CHD4 recruitment and chromatin remodeling activity at DNA breaks is promoted by early poly(ADP-ribose)-dependent chromatin relaxation. Nucleic Acids Res 2018;46:6087-98. [PMID: 29733391 DOI: 10.1093/nar/gky334] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
388 Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, Nakazawa Y, Ogi T, Harada H, Agama K, Nakamura J, Asada R, Fujiike H, Sakuma T, Yamamoto T, Murai J, Hiraoka M, Koike K, Pommier Y, Takeda S, Hirota K. ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. PLoS One 2017;12:e0188320. [PMID: 29149203 DOI: 10.1371/journal.pone.0188320] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
389 Knies K, Inano S, Ramírez MJ, Ishiai M, Surrallés J, Takata M, Schindler D. Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia. J Clin Invest 2017;127:3013-27. [PMID: 28691929 DOI: 10.1172/JCI92069] [Cited by in Crossref: 106] [Cited by in F6Publishing: 58] [Article Influence: 26.5] [Reference Citation Analysis]
390 Li X, Li C, Jin J, Wang J, Huang J, Ma Z, Huang X, He X, Zhou Y, Xu Y, Yu M, Huang S, Yan X, Li F, Pan J, Wang Y, Yu Y, Jin J. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMedicine 2018;38:47-56. [PMID: 30472087 DOI: 10.1016/j.ebiom.2018.11.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
391 Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, Taylor-Harding B, Tanaka H, Orsulic S, Junza A, Yanes O, Muñoz-Pinedo C, Palomero L, Pujana MÀ, Perales JC, Viñals F. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. EMBO Mol Med 2020;12:e11217. [PMID: 32400970 DOI: 10.15252/emmm.201911217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
392 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
393 Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S. A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Rep 2018;23:918-29. [PMID: 29669295 DOI: 10.1016/j.celrep.2018.03.093] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
394 Sun Y, Liu Y, Ma X, Hu H. The Influence of Cell Cycle Regulation on Chemotherapy. Int J Mol Sci 2021;22:6923. [PMID: 34203270 DOI: 10.3390/ijms22136923] [Reference Citation Analysis]
395 Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clin Cancer Res 2020;26:1690-9. [PMID: 31900275 DOI: 10.1158/1078-0432.CCR-19-2000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 31.0] [Reference Citation Analysis]
396 Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, Krishnasamy V, Levy E, Mammen A, Nichols S, Chen Y, Velcheti V, Yin F, Szabo E, Pommier Y, Steinberg SM, Trepel JB, Raffeld M, Young HA, Khan J, Hewitt S, Lee JM. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. J Thorac Oncol. 2019;14:1447-1457. [PMID: 31063862 DOI: 10.1016/j.jtho.2019.04.026] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 22.0] [Reference Citation Analysis]
397 Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther 2015;14:920-30. [PMID: 25824335 DOI: 10.1158/1535-7163.MCT-14-0474] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
398 Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
399 LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res 2016;22:3227-37. [PMID: 26842236 DOI: 10.1158/1078-0432.CCR-15-0652] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 11.2] [Reference Citation Analysis]
400 Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clin Cancer Res 2017;23:1397-406. [PMID: 27663600 DOI: 10.1158/1078-0432.CCR-16-1546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
401 Gmeiner WH, Gearhart PJ, Pommier Y, Nakamura J. F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. Future Oncol 2016;12:2183-8. [PMID: 27333295 DOI: 10.2217/fon-2016-0127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
402 Dale Rein I, Solberg Landsverk K, Micci F, Patzke S, Stokke T. Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. Cell Cycle. 2015;14:3248-3260. [PMID: 26312527 DOI: 10.1080/15384101.2015.1085137] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
403 Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 2015;62:91-8. [PMID: 25263539 DOI: 10.1002/pbc.25201] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
404 Faraoni I, Graziani G. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel) 2018;10:E487. [PMID: 30518089 DOI: 10.3390/cancers10120487] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 26.3] [Reference Citation Analysis]
405 Bell NAW, Haynes PJ, Brunner K, de Oliveira TM, Flocco MM, Hoogenboom BW, Molloy JE. Single-molecule measurements reveal that PARP1 condenses DNA by loop stabilization. Sci Adv 2021;7:eabf3641. [PMID: 34380612 DOI: 10.1126/sciadv.abf3641] [Reference Citation Analysis]
406 Zandarashvili L, Langelier MF, Velagapudi UK, Hancock MA, Steffen JD, Billur R, Hannan ZM, Wicks AJ, Krastev DB, Pettitt SJ, Lord CJ, Talele TT, Pascal JM, Black BE. Structural basis for allosteric PARP-1 retention on DNA breaks. Science 2020;368:eaax6367. [PMID: 32241924 DOI: 10.1126/science.aax6367] [Cited by in Crossref: 63] [Cited by in F6Publishing: 45] [Article Influence: 63.0] [Reference Citation Analysis]
407 Murai J, Marchand C, Shahane SA, Sun H, Huang R, Zhang Y, Chergui A, Ji J, Doroshow JH, Jadhav A, Takeda S, Xia M, Pommier Y. Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA Repair (Amst) 2014;21:177-82. [PMID: 24794403 DOI: 10.1016/j.dnarep.2014.03.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
408 Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, Rutherford T, Nagaria P, Bentzen SM, Seidman MM, Baer MR, Lapidus RG, Baylin SB, Rassool FV. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer. Cancer Cell 2016;30:637-50. [PMID: 27728808 DOI: 10.1016/j.ccell.2016.09.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 20.0] [Reference Citation Analysis]
409 Zhu H, Swami U, Preet R, Zhang J. Harnessing DNA Replication Stress for Novel Cancer Therapy. Genes (Basel) 2020;11:E990. [PMID: 32854236 DOI: 10.3390/genes11090990] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
410 Reilly SW, Puentes LN, Hsieh CJ, Makvandi M, Mach RH. Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions. ACS Omega 2018;3:9997-10001. [PMID: 30198004 DOI: 10.1021/acsomega.8b00896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
411 Liu C, Srihari S, Cao KA, Chenevix-Trench G, Simpson PT, Ragan MA, Khanna KK. A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Res 2014;42:6106-27. [PMID: 24792170 DOI: 10.1093/nar/gku284] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
412 Guo E, Ishii Y, Mueller J, Srivatsan A, Gahman T, Putnam CD, Wang JYJ, Kolodner RD. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination. Proc Natl Acad Sci U S A 2020;117:19415-24. [PMID: 32719125 DOI: 10.1073/pnas.2009237117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
413 Pandey N, Black BE. Rapid Detection and Signaling of DNA Damage by PARP-1. Trends Biochem Sci 2021;46:744-57. [PMID: 33674152 DOI: 10.1016/j.tibs.2021.01.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
414 Thompson MK, Sobol RW, Prakash A. Exploiting DNA Endonucleases to Advance Mechanisms of DNA Repair. Biology (Basel) 2021;10:530. [PMID: 34198612 DOI: 10.3390/biology10060530] [Reference Citation Analysis]
415 Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406. [PMID: 25779564 DOI: 10.1200/JCO.2014.58.8848] [Cited by in Crossref: 223] [Cited by in F6Publishing: 131] [Article Influence: 37.2] [Reference Citation Analysis]
416 Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019;16:81-104. [PMID: 30356138 DOI: 10.1038/s41571-018-0114-z] [Cited by in Crossref: 285] [Cited by in F6Publishing: 231] [Article Influence: 142.5] [Reference Citation Analysis]
417 Rudolph J, Roberts G, Luger K. Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs. Nat Commun 2021;12:736. [PMID: 33531508 DOI: 10.1038/s41467-021-20998-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
418 Goss KL, Gordon DJ. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget 2016;7:63003-19. [PMID: 27557498 DOI: 10.18632/oncotarget.11416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
419 Zonneville J, Wang M, Alruwaili MM, Smith B, Melnick M, Eng KH, Melendy T, Park BH, Iyer R, Fountzilas C, Bakin AV. Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Commun Biol 2021;4:862. [PMID: 34253820 DOI: 10.1038/s42003-021-02370-0] [Reference Citation Analysis]
420 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
421 Moudry P, Watanabe K, Wolanin KM, Bartkova J, Wassing IE, Watanabe S, Strauss R, Troelsgaard Pedersen R, Oestergaard VH, Lisby M. TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity. J Cell Biol. 2016;212:281-288. [PMID: 26811421 DOI: 10.1083/jcb.201507042] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
422 Hernandez AL, Young CD, Bian L, Weigel K, Nolan K, Frederick B, Han G, He G, Devon Trahan G, Rudolph MC, Jones KL, Oweida AJ, Karam SD, Raben D, Wang XJ. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res 2020;26:3058-70. [PMID: 32139402 DOI: 10.1158/1078-0432.CCR-19-0514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
423 Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev 2020;34:360-94. [PMID: 32029455 DOI: 10.1101/gad.334516.119] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 83.0] [Reference Citation Analysis]
424 Gatti M, Imhof R, Huang Q, Baudis M, Altmeyer M. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency. Cell Rep 2020;32:107985. [PMID: 32755579 DOI: 10.1016/j.celrep.2020.107985] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
425 Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest 2018;128:2116-26. [PMID: 29509546 DOI: 10.1172/JCI97992] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 17.3] [Reference Citation Analysis]
426 Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 2014;34:3828-42. [PMID: 25092866 DOI: 10.1128/MCB.01646-13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
427 Kim JJ, Lee SY, Choi JH, Woo HG, Xhemalce B, Miller KM. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells. Mol Cell 2020;80:327-344.e8. [PMID: 32966758 DOI: 10.1016/j.molcel.2020.08.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
428 Rozacky J, Nemec AA, Sweasy JB, Kidane D. Gastric cancer associated variant of DNA polymerase beta (Leu22Pro) promotes DNA replication associated double strand breaks. Oncotarget 2015;6:24474-87. [PMID: 26090616 DOI: 10.18632/oncotarget.4426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
429 Patel M, Nowsheen S, Maraboyina S, Xia F. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell Biosci. 2020;10:35. [PMID: 32180937 DOI: 10.1186/s13578-020-00390-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 22.0] [Reference Citation Analysis]
430 Huynh JC, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers (Basel). 2020;12. [PMID: 32384640 DOI: 10.3390/cancers12051168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
431 Ferrari N, Granata I, Capaia M, Piccirillo M, Guarracino MR, Venè R, Brizzolara A, Petretto A, Inglese E, Morini M, Astigiano S, Amaro AA, Boccardo F, Balbi C, Barboro P. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer. Cell Commun Signal 2017;15:51. [PMID: 29216878 DOI: 10.1186/s12964-017-0206-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
432 Lodovichi S, Mercatanti A, Cervelli T, Galli A. Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets. Oncotarget 2019;10:2722-37. [PMID: 31105872 DOI: 10.18632/oncotarget.26812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
433 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 2016;115:1157-73. [PMID: 27736844 DOI: 10.1038/bjc.2016.311] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 22.6] [Reference Citation Analysis]
434 Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors--three and counting. Cancer Discov 2013;3:20-3. [PMID: 23319766 DOI: 10.1158/2159-8290.CD-12-0514] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
435 Visnes T, Benítez-Buelga C, Cázares-Körner A, Sanjiv K, Hanna BMF, Mortusewicz O, Rajagopal V, Albers JJ, Hagey DW, Bekkhus T, Eshtad S, Baquero JM, Masuyer G, Wallner O, Müller S, Pham T, Göktürk C, Rasti A, Suman S, Torres-Ruiz R, Sarno A, Wiita E, Homan EJ, Karsten S, Marimuthu K, Michel M, Koolmeister T, Scobie M, Loseva O, Almlöf I, Unterlass JE, Pettke A, Boström J, Pandey M, Gad H, Herr P, Jemth AS, El Andaloussi S, Kalderén C, Rodriguez-Perales S, Benítez J, Krokan HE, Altun M, Stenmark P, Berglund UW, Helleday T. Targeting OGG1 arrests cancer cell proliferation by inducing replication stress. Nucleic Acids Res 2020;48:12234-51. [PMID: 33211885 DOI: 10.1093/nar/gkaa1048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
436 Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 2015;21:819-32. [PMID: 25500058 DOI: 10.1158/1078-0432.CCR-14-2572] [Cited by in Crossref: 82] [Cited by in F6Publishing: 48] [Article Influence: 11.7] [Reference Citation Analysis]
437 Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci 2020;111:3111-21. [PMID: 32639661 DOI: 10.1111/cas.14565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
438 Sahaboglu A, Barth M, Secer E, Amo EM, Urtti A, Arsenijevic Y, Zrenner E, Paquet-Durand F. Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration. Sci Rep 2016;6:39537. [PMID: 28004814 DOI: 10.1038/srep39537] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
439 Pacenta HL, Allen-Rhoades W, Langenau D, Houghton PJ, Keller C, Heske CM, Deel MD, Linardic CM, Shern JF, Stewart E, Turpin B, Harrison DJ, Khan J, Mascarenhas L, Skapek SX, Meyer WH, Hawkins DS, Chen EY, Amatruda JF, Hingorani P, Laetsch TW. Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. J Clin Med 2021;10:1416. [PMID: 33915882 DOI: 10.3390/jcm10071416] [Reference Citation Analysis]
440 Wang C, Tang H, Geng A, Dai B, Zhang H, Sun X, Chen Y, Qiao Z, Zhu H, Yang J, Chen J, He Q, Qin N, Xie J, Tan R, Wan X, Gao S, Jiang Y, Sun FL, Mao Z. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors. Proc Natl Acad Sci U S A 2020;117:26356-65. [PMID: 33020270 DOI: 10.1073/pnas.2002917117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
441 Alemasova EE, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res. 2019;47:3811-3827. [PMID: 30799503 DOI: 10.1093/nar/gkz120] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 43.5] [Reference Citation Analysis]
442 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 198] [Article Influence: 33.4] [Reference Citation Analysis]
443 Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun 2018;9:1849. [PMID: 29748565 DOI: 10.1038/s41467-018-03917-2] [Cited by in Crossref: 139] [Cited by in F6Publishing: 114] [Article Influence: 46.3] [Reference Citation Analysis]
444 Michelena J, Lezaja A, Teloni F, Schmid T, Imhof R, Altmeyer M. Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nat Commun 2018;9:2678. [PMID: 29992957 DOI: 10.1038/s41467-018-05031-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
445 Cortesi L, Rugo HS, Jackisch C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol 2021;16:255-82. [PMID: 33710534 DOI: 10.1007/s11523-021-00796-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
446 Knezevic CE, Wright G, Rix LLR, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chem Biol 2016;23:1490-503. [PMID: 27866910 DOI: 10.1016/j.chembiol.2016.10.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 10.6] [Reference Citation Analysis]
447 Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 2016;16:1337-51. [PMID: 27828713 DOI: 10.1080/14737159.2016.1259069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
448 Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst) 2018;71:177-82. [PMID: 30177435 DOI: 10.1016/j.dnarep.2018.08.022] [Cited by in Crossref: 90] [Cited by in F6Publishing: 71] [Article Influence: 30.0] [Reference Citation Analysis]
449 Li CJ, Tzeng YT, Chiu YH, Lin HY, Hou MF, Chu PY. Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:2978. [PMID: 34198652 DOI: 10.3390/cancers13122978] [Reference Citation Analysis]
450 Fielden J, Ruggiano A, Popović M, Ramadan K. DNA protein crosslink proteolysis repair: From yeast to premature ageing and cancer in humans. DNA Repair (Amst) 2018;71:198-204. [PMID: 30170832 DOI: 10.1016/j.dnarep.2018.08.025] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
451 Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol 2018;14:3101-10. [PMID: 30105925 DOI: 10.2217/fon-2018-0215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
452 Langelier MF, Riccio AA, Pascal JM. PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. Nucleic Acids Res 2014;42:7762-75. [PMID: 24928857 DOI: 10.1093/nar/gku474] [Cited by in Crossref: 136] [Cited by in F6Publishing: 120] [Article Influence: 19.4] [Reference Citation Analysis]
453 Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br J Cancer 2017;117:113-23. [PMID: 28535155 DOI: 10.1038/bjc.2017.133] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 13.8] [Reference Citation Analysis]
454 King D, Li XD, Almeida GS, Kwok C, Gravells P, Harrison D, Burke S, Hallsworth A, Jamin Y, George S, Robinson SP, Lord CJ, Poon E, Yeomanson D, Chesler L, Bryant HE. MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. Oncotarget 2020;11:2141-59. [PMID: 32577161 DOI: 10.18632/oncotarget.27329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
455 Dale Rein I, Stokke C, Jalal M, Myklebust JH, Patzke S, Stokke T. New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX. Cell Cycle 2015;14:3261-9. [PMID: 26317799 DOI: 10.1080/15384101.2015.1087617] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
456 Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer 2016;16:621. [PMID: 27515310 DOI: 10.1186/s12885-016-2656-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
457 Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med 2014;7:307-16. [PMID: 25342917 DOI: 10.2147/PGPM.S39765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
458 Makvandi M, Xu K, Lieberman BP, Anderson RC, Effron SS, Winters HD, Zeng C, McDonald ES, Pryma DA, Greenberg RA, Mach RH. A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. Cancer Res 2016;76:4516-24. [PMID: 27261505 DOI: 10.1158/0008-5472.CAN-16-0416] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
459 Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014;7:203-15. [PMID: 25206307 DOI: 10.2147/PGPM.S52762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 49] [Article Influence: 1.3] [Reference Citation Analysis]
460 Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer 2018;119:141-52. [PMID: 29867226 DOI: 10.1038/s41416-018-0127-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 23.0] [Reference Citation Analysis]
461 Parchment RE, Doroshow JH. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Semin Oncol 2016;43:514-25. [PMID: 27663483 DOI: 10.1053/j.seminoncol.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
462 Roguev A, Talbot D, Negri GL, Shales M, Cagney G, Bandyopadhyay S, Panning B, Krogan NJ. Quantitative genetic-interaction mapping in mammalian cells. Nat Methods 2013;10:432-7. [PMID: 23407553 DOI: 10.1038/nmeth.2398] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 10.8] [Reference Citation Analysis]
463 Abbotts R, Thompson N, Madhusudan S. DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag Res 2014;6:77-92. [PMID: 24600246 DOI: 10.2147/CMAR.S50497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
464 Rank L, Veith S, Gwosch EC, Demgenski J, Ganz M, Jongmans MC, Vogel C, Fischbach A, Buerger S, Fischer JM, Zubel T, Stier A, Renner C, Schmalz M, Beneke S, Groettrup M, Kuiper RP, Bürkle A, Ferrando-May E, Mangerich A. Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells. Nucleic Acids Res 2016;44:10386-405. [PMID: 27694308 DOI: 10.1093/nar/gkw859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
465 Sehouli J, Braicu EI, Chekerov R. PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives. Geburtshilfe Frauenheilkd 2016;76:164-9. [PMID: 26941449 DOI: 10.1055/s-0035-1558185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
466 Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 2016;108. [PMID: 26848151 DOI: 10.1093/jnci/djv437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
467 Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Front Oncol 2018;8:670. [PMID: 30723695 DOI: 10.3389/fonc.2018.00670] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
468 Wang F, Zhu S, Fisher LA, Wang L, Eurek NJ, Wahl JK 3rd, Lan L, Peng A. Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair. Cancer Res 2019;79:2526-35. [PMID: 30733193 DOI: 10.1158/0008-5472.CAN-18-1673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
469 Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers (Basel) 2020;12:E1206. [PMID: 32403357 DOI: 10.3390/cancers12051206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
470 Jiang Q, Greenberg RA. Deciphering the BRCA1 Tumor Suppressor Network. J Biol Chem 2015;290:17724-32. [PMID: 26048987 DOI: 10.1074/jbc.R115.667931] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
471 Geenen JJJ, Dackus GMHE, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema ADR, Beijnen JH, Schellens JHM, Linn SC. A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. Int J Cancer 2021;148:3041-50. [PMID: 33539540 DOI: 10.1002/ijc.33498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
472 Naito Y, Kuboki Y, Ikeda M, Harano K, Matsubara N, Toyoizumi S, Mori Y, Hori N, Nagasawa T, Kogawa T. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study. Invest New Drugs 2021. [PMID: 34160752 DOI: 10.1007/s10637-021-01120-7] [Reference Citation Analysis]
473 Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors. Oncotarget 2016;7:7701-14. [PMID: 26713604 DOI: 10.18632/oncotarget.6715] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
474 Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S. Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. Br J Cancer 2020;122:483-90. [PMID: 31813938 DOI: 10.1038/s41416-019-0674-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
475 Herzog M, Puddu F, Coates J, Geisler N, Forment JV, Jackson SP. Detection of functional protein domains by unbiased genome-wide forward genetic screening. Sci Rep 2018;8:6161. [PMID: 29670134 DOI: 10.1038/s41598-018-24400-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
476 Augustine T, Maitra R, Zhang J, Nayak J, Goel S. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib. Invest New Drugs. 2019;37:948-960. [PMID: 30612311 DOI: 10.1007/s10637-018-00717-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
477 Verma P, Zhou Y, Cao Z, Deraska PV, Deb M, Arai E, Li W, Shao Y, Puentes L, Li Y, Patankar S, Mach RH, Faryabi RB, Shi J, Greenberg RA. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells. Nat Cell Biol 2021;23:160-71. [PMID: 33462394 DOI: 10.1038/s41556-020-00624-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
478 Hewitt G, Borel V, Segura-Bayona S, Takaki T, Ruis P, Bellelli R, Lehmann LC, Sommerova L, Vancevska A, Tomas-Loba A, Zhu K, Cooper C, Fugger K, Patel H, Goldstone R, Schneider-Luftman D, Herbert E, Stamp G, Brough R, Pettitt S, Lord CJ, West SC, Ahel I, Ahel D, Chapman JR, Deindl S, Boulton SJ. Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. Mol Cell 2021;81:767-783.e11. [PMID: 33333017 DOI: 10.1016/j.molcel.2020.12.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
479 Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5:1137-1154. [PMID: 26463832 DOI: 10.1158/2159-8290.cd-15-0714] [Cited by in Crossref: 347] [Cited by in F6Publishing: 190] [Article Influence: 57.8] [Reference Citation Analysis]
480 Hou WH, Chen SH, Yu X. Poly-ADP ribosylation in DNA damage response and cancer therapy. Mutat Res Rev Mutat Res 2019;780:82-91. [PMID: 31395352 DOI: 10.1016/j.mrrev.2017.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
481 Reisländer T, Lombardi EP, Groelly FJ, Miar A, Porru M, Di Vito S, Wright B, Lockstone H, Biroccio A, Harris A, Londoño-Vallejo A, Tarsounas M. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun 2019;10:3143. [PMID: 31316060 DOI: 10.1038/s41467-019-11048-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 24.5] [Reference Citation Analysis]
482 Valabrega G, Scotto G, Tuninetti V, Pani A, Scaglione F. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. Int J Mol Sci 2021;22:4203. [PMID: 33921561 DOI: 10.3390/ijms22084203] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
483 Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther 2018;12:1501-9. [PMID: 29881257 DOI: 10.2147/DDDT.S124447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
484 Horton JK, Gassman NR, Dunigan BD, Stefanick DF, Wilson SH. DNA polymerase β-dependent cell survival independent of XRCC1 expression. DNA Repair (Amst) 2015;26:23-9. [PMID: 25541391 DOI: 10.1016/j.dnarep.2014.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
485 Ward TA, McHugh PJ, Durant ST. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes. PLoS One 2017;12:e0179278. [PMID: 28628639 DOI: 10.1371/journal.pone.0179278] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
486 Owens C, Abbott LS, Gupta AA. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr Drugs 2013;15:473-92. [PMID: 23760780 DOI: 10.1007/s40272-013-0037-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
487 Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res 2018;37:153. [PMID: 30012171 DOI: 10.1186/s13046-018-0810-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
488 Vohhodina J, Toomire KJ, Petit SA, Micevic G, Kumari G, Botchkarev VV Jr, Li Z, Livingston DM, Hu Y. RAP80 and BRCA1 PARsylation protect chromosome integrity by preventing retention of BRCA1-B/C complexes in DNA repair foci. Proc Natl Acad Sci U S A 2020;117:2084-91. [PMID: 31932421 DOI: 10.1073/pnas.1908003117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
489 Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, Heffernan TP, Clump DA, Faust AZ, Ferris RL, Myers JN, Frederick MJ, Mason KA, Meyn RE, Pickering CR, Skinner HD. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol 2021;97:1121-8. [PMID: 32073931 DOI: 10.1080/09553002.2020.1730014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
490 Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. Clin Cancer Res 2019;25:6206-16. [PMID: 31409613 DOI: 10.1158/1078-0432.CCR-19-0419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
491 Barretina-Ginesta MP. DNA damaging agents in ovarian cancer. EJC Suppl 2020;15:67-72. [PMID: 33240444 DOI: 10.1016/j.ejcsup.2020.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
492 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
493 Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Mol Cancer Res 2018;16:1092-102. [PMID: 29592899 DOI: 10.1158/1541-7786.MCR-18-0106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
494 Matsuno Y, Hyodo M, Fujimori H, Shimizu A, Yoshioka KI. Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules. Cancers (Basel). 2018;10:pii: E364. [PMID: 30274183 DOI: 10.3390/cancers10100364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
495 Lee HS, Lee NC, Kouprina N, Kim JH, Kagansky A, Bates S, Trepel JB, Pommier Y, Sackett D, Larionov V. Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. Cancer Res 2016;76:902-11. [PMID: 26837770 DOI: 10.1158/0008-5472.CAN-15-1617] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 8.4] [Reference Citation Analysis]
496 Reinbolt RE, Hays JL. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front Oncol 2013;3:237. [PMID: 24098868 DOI: 10.3389/fonc.2013.00237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
497 Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs R D. 2020;20:55-73. [PMID: 32215876 DOI: 10.1007/s40268-020-00301-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
498 Noll A, Illuzzi G, Amé JC, Dantzer F, Schreiber V. PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency. Cancer Cell Int 2016;16:53. [PMID: 27375368 DOI: 10.1186/s12935-016-0333-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
499 Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, Richardson L, Benes CH, Stratton MR, McDermott U, Jackson SP, Garnett MJ. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. PLoS One 2015;10:e0140988. [PMID: 26505995 DOI: 10.1371/journal.pone.0140988] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
500 Pishas KI, Lessnick SL. Recent advances in targeted therapy for Ewing sarcoma. F1000Res 2016;5:F1000 Faculty Rev-2077. [PMID: 27635231 DOI: 10.12688/f1000research.8631.1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
501 Ngo G, Hyatt S, Grimstead J, Jones R, Hendrickson E, Pepper C, Baird D. PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. Oncotarget 2018;9:37549-63. [PMID: 30680069 DOI: 10.18632/oncotarget.26499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
502 Keuss MJ, Hjerpe R, Hsia O, Gourlay R, Burchmore R, Trost M, Kurz T. Unanchored tri-NEDD8 inhibits PARP-1 to protect from oxidative stress-induced cell death. EMBO J 2019;38:e100024. [PMID: 30804002 DOI: 10.15252/embj.2018100024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
503 Chiu LY, Gong F, Miller KM. Bromodomain proteins: repairing DNA damage within chromatin. Philos Trans R Soc Lond B Biol Sci 2017;372:20160286. [PMID: 28847823 DOI: 10.1098/rstb.2016.0286] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
504 Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, Jones GN, James N, Chabbert CD, Stott J, Dean E, Lau A, Young LA. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39:4869-4883. [PMID: 32444694 DOI: 10.1038/s41388-020-1328-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 28.0] [Reference Citation Analysis]
505 Jensen RB, Rothenberg E. Preserving genome integrity in human cells via DNA double-strand break repair. Mol Biol Cell 2020;31:859-65. [PMID: 32286930 DOI: 10.1091/mbc.E18-10-0668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
506 Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT, Rudin CM. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clin Cancer Res 2018;24:5143-52. [PMID: 29945991 DOI: 10.1158/1078-0432.CCR-18-0401] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 12.3] [Reference Citation Analysis]
507 Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. J Ovarian Res 2021;14:68. [PMID: 33993885 DOI: 10.1186/s13048-021-00803-2] [Reference Citation Analysis]
508 Jang A, Sartor O, Barata PC, Paller CJ. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2020;12:E3467. [PMID: 33233320 DOI: 10.3390/cancers12113467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
509 Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer 2017;123:1912-24. [PMID: 28323334 DOI: 10.1002/cncr.30631] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
510 Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R. Successes and Challenges of PARP Inhibitors in Cancer Therapy. Front Oncol 2015;5:222. [PMID: 26528434 DOI: 10.3389/fonc.2015.00222] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
511 Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20. [PMID: 26775620 DOI: 10.1038/nrc.2015.21] [Cited by in Crossref: 576] [Cited by in F6Publishing: 490] [Article Influence: 115.2] [Reference Citation Analysis]
512 Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610-621. [PMID: 28676700 DOI: 10.1038/nrm.2017.53] [Cited by in Crossref: 428] [Cited by in F6Publishing: 362] [Article Influence: 107.0] [Reference Citation Analysis]
513 Qiu B, Kline C, Mueller S. Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges. Front Oncol 2021;11:674596. [PMID: 34277419 DOI: 10.3389/fonc.2021.674596] [Reference Citation Analysis]
514 Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC. First-Line Management of Advanced High-Grade Serous Ovarian Cancer. Curr Oncol Rep 2020;22:64. [PMID: 32494876 DOI: 10.1007/s11912-020-00933-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
515 Park JS, Lee ME, Jang WS, Rha KH, Lee SH, Lee J, Ham WS. The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity. Cancers (Basel) 2021;13:2574. [PMID: 34073906 DOI: 10.3390/cancers13112574] [Reference Citation Analysis]
516 Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov. 2014;4:280-291. [PMID: 24550033 DOI: 10.1158/2159-8290.cd-13-0337] [Cited by in Crossref: 61] [Cited by in F6Publishing: 36] [Article Influence: 8.7] [Reference Citation Analysis]
517 Gassman NR, Wilson SH. Micro-irradiation tools to visualize base excision repair and single-strand break repair. DNA Repair (Amst) 2015;31:52-63. [PMID: 25996408 DOI: 10.1016/j.dnarep.2015.05.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
518 LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 2019;20:e15-28. [PMID: 30614472 DOI: 10.1016/S1470-2045(18)30786-1] [Cited by in Crossref: 87] [Cited by in F6Publishing: 38] [Article Influence: 87.0] [Reference Citation Analysis]
519 Guppy BJ, McManus KJ. Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. Cell Oncol (Dordr) 2017;40:281-92. [PMID: 28462496 DOI: 10.1007/s13402-017-0323-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
520 Taniguchi H, Sen T, Rudin CM. Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Front Oncol 2020;10:741. [PMID: 32509576 DOI: 10.3389/fonc.2020.00741] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
521 Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S. Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility. Nat Commun 2020;11:2375. [PMID: 32398776 DOI: 10.1038/s41467-020-16078-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
522 Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 2018;9:37080-96. [PMID: 30647846 DOI: 10.18632/oncotarget.26354] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
523 Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 2018;33:401-416.e8. [PMID: 29533782 DOI: 10.1016/j.ccell.2018.01.019] [Cited by in Crossref: 106] [Cited by in F6Publishing: 84] [Article Influence: 35.3] [Reference Citation Analysis]
524 Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene 2018;37:208-17. [PMID: 28925391 DOI: 10.1038/onc.2017.311] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
525 Zhao H, Yang Q, Hu Y, Zhang J. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells. Oncol Rep 2018;40:3223-34. [PMID: 30272286 DOI: 10.3892/or.2018.6716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
526 Turk AA, Wisinski KB. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 2018;124:2498-506. [PMID: 29660759 DOI: 10.1002/cncr.31307] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
527 Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer 2018;89:19-26. [PMID: 29223478 DOI: 10.1016/j.ejca.2017.11.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 18.5] [Reference Citation Analysis]
528 Chang M, Wang H, Niu J, Song Y, Zou Z. Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity. Front Pharmacol 2020;11:610205. [PMID: 33519476 DOI: 10.3389/fphar.2020.610205] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
529 Pezaro C. PARP inhibitor combinations in prostate cancer. Ther Adv Med Oncol 2020;12:1758835919897537. [PMID: 32215055 DOI: 10.1177/1758835919897537] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
530 Gupta M, Iyer R, Fountzilas C. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers (Basel) 2019;11:E1980. [PMID: 31835379 DOI: 10.3390/cancers11121980] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
531 Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. Int J Biol Sci 2019;15:962-72. [PMID: 31182917 DOI: 10.7150/ijbs.30721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
532 Sun R, Luo H, Su J, Di S, Zhou M, Shi B, Sun Y, Du G, Zhang H, Jiang H, Li Z. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Mol Ther 2021;29:60-74. [PMID: 33010818 DOI: 10.1016/j.ymthe.2020.09.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
533 Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis 2020;23:24-37. [PMID: 31197228 DOI: 10.1038/s41391-019-0153-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
534 Kim C, Wang XD, Yu Y. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. Elife 2020;9:e60637. [PMID: 32844745 DOI: 10.7554/eLife.60637] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
535 Ganz M, Vogel C, Czada C, Jörke V, Gwosch EC, Kleiner R, Pierzynska-Mach A, Zanacchi FC, Diaspro A, Kappes F, Bürkle A, Ferrando-May E. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress. PLoS One 2019;14:e0213130. [PMID: 31408463 DOI: 10.1371/journal.pone.0213130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
536 Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 2015;7:189-203. [PMID: 25678824 DOI: 10.2147/IJWH.S52379] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
537 Lu Y, Liu Y, Pang Y, Pacak K, Yang C. Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. Pharmacol Ther 2018;188:168-75. [PMID: 29621593 DOI: 10.1016/j.pharmthera.2018.03.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
538 Gomez MK, Illuzzi G, Colomer C, Churchman M, Hollis RL, O'Connor MJ, Gourley C, Leo E, Melton DW. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. Cancers (Basel) 2020;12:E1503. [PMID: 32526907 DOI: 10.3390/cancers12061503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
539 Klotz DM, Wimberger P. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies? Arch Gynecol Obstet 2020;302:1087-102. [PMID: 32833070 DOI: 10.1007/s00404-020-05677-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
540 Prati B, Marangoni B, Boccardo E. Human papillomavirus and genome instability: from productive infection to cancer. Clinics (Sao Paulo) 2018;73:e539s. [PMID: 30208168 DOI: 10.6061/clinics/2018/e539s] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
541 Brettrager EJ, Segura IA, van Waardenburg RCAM. Tyrosyl-DNA Phosphodiesterase I N-Terminal Domain Modifications and Interactions Regulate Cellular Function. Genes (Basel) 2019;10:E897. [PMID: 31698852 DOI: 10.3390/genes10110897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
542 Alemasova EE, Naumenko KN, Kurgina TA, Anarbaev RO, Lavrik OI. The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors. Oncotarget 2018;9:23349-65. [PMID: 29805738 DOI: 10.18632/oncotarget.25158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
543 Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 2014;3:1579-94. [PMID: 25124282 DOI: 10.1002/cam4.317] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
544 Langelier MF, Eisemann T, Riccio AA, Pascal JM. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr Opin Struct Biol. 2018;53:187-198. [PMID: 30481609 DOI: 10.1016/j.sbi.2018.11.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 21.3] [Reference Citation Analysis]
545 Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol 2018;81:647-58. [PMID: 29464354 DOI: 10.1007/s00280-018-3532-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
546 Drakes ML, Stiff PJ. Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. Adv Exp Med Biol 2021;1330:33-54. [PMID: 34339029 DOI: 10.1007/978-3-030-73359-9_3] [Reference Citation Analysis]
547 Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem 2017;24:1586-606. [PMID: 27978798 DOI: 10.2174/0929867323666161214114948] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
548 Boonen RACM, Vreeswijk MPG, van Attikum H. Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction. Front Mol Biosci 2020;7:169. [PMID: 33195396 DOI: 10.3389/fmolb.2020.00169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
549 Medina MA, Oza G, Sharma A, Arriaga LG, Hernández Hernández JM, Rotello VM, Ramirez JT. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health 2020;17:E2078. [PMID: 32245065 DOI: 10.3390/ijerph17062078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
550 Weidema ME, Desar IME, Hillebrandt-Roeffen MHS, van Erp AEM, Masuzawa M, Flucke UE, van der Graaf WTA, Versleijen-Jonkers YMH; PALGA-group. PARP inhibition in UV-associated angiosarcoma preclinical models. J Cancer Res Clin Oncol 2021;147:2579-90. [PMID: 34085099 DOI: 10.1007/s00432-021-03678-4] [Reference Citation Analysis]
551 Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013;8:82-95. [PMID: 23259582 DOI: 10.1021/cb300648v] [Cited by in Crossref: 519] [Cited by in F6Publishing: 436] [Article Influence: 64.9] [Reference Citation Analysis]
552 Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015;13:188. [PMID: 26268938 DOI: 10.1186/s12916-015-0425-1] [Cited by in Crossref: 160] [Cited by in F6Publishing: 139] [Article Influence: 26.7] [Reference Citation Analysis]
553 Orta ML, Höglund A, Calderón-Montaño JM, Domínguez I, Burgos-Morón E, Visnes T, Pastor N, Ström C, López-lázaro M, Helleday T. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions. Nucleic Acids Res 2014;42:9108-20. [PMID: 25074383 DOI: 10.1093/nar/gku638] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
554 de Castro E Gloria H, Jesuíno Nogueira L, Bencke Grudzinski P, da Costa Ghignatti PV, Guecheva TN, Motta Leguisamo N, Saffi J. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. BMC Cancer 2021;21:448. [PMID: 33888065 DOI: 10.1186/s12885-021-08188-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
555 Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun 2017;8:374. [PMID: 28851861 DOI: 10.1038/s41467-017-00393-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 19.3] [Reference Citation Analysis]
556 Laverty DJ, Mortimer IP, Greenberg MM. Mechanistic Insight through Irreversible Inhibition: DNA Polymerase θ Uses a Common Active Site for Polymerase and Lyase Activities. J Am Chem Soc 2018;140:9034-7. [PMID: 29998737 DOI: 10.1021/jacs.8b04158] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
557 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 39] [Article Influence: 15.8] [Reference Citation Analysis]
558 Liu L, Kong M, Gassman NR, Freudenthal BD, Prasad R, Zhen S, Watkins SC, Wilson SH, Van Houten B. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1. Nucleic Acids Res 2017;45:12834-47. [PMID: 29121337 DOI: 10.1093/nar/gkx1047] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 16.0] [Reference Citation Analysis]
559 Borst GR, Kumareswaran R, Yücel H, Telli S, Do T, McKee T, Zafarana G, Jonkers J, Verheij M, O'Connor MJ, Rottenberg S, Bristow RG. Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget 2017;8:87638-46. [PMID: 29152107 DOI: 10.18632/oncotarget.20936] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
560 Panday A, Willis NA, Elango R, Menghi F, Duffey EE, Liu ET, Scully R. FANCM regulates repair pathway choice at stalled replication forks. Mol Cell 2021;81:2428-2444.e6. [PMID: 33882298 DOI: 10.1016/j.molcel.2021.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
561 Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, Wilson SH. Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res 2014;12:1128-39. [PMID: 24770870 DOI: 10.1158/1541-7786.MCR-13-0502] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
562 Qi F, Qin WX, Zang YS. Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways. Oncol Lett 2019;17:2905-14. [PMID: 30854067 DOI: 10.3892/ol.2019.9884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
563 Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J Cancer 2016;114:713-5. [PMID: 27022824 DOI: 10.1038/bjc.2016.67] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 18.6] [Reference Citation Analysis]
564 Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32-40. [PMID: 24225019 DOI: 10.1093/annonc/mdt384] [Cited by in Crossref: 206] [Cited by in F6Publishing: 174] [Article Influence: 25.8] [Reference Citation Analysis]
565 Haynes B, Murai J, Lee JM. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev 2018;71:1-7. [PMID: 30269007 DOI: 10.1016/j.ctrv.2018.09.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 15.3] [Reference Citation Analysis]
566 Pellegrino B, Musolino A, Llop-Guevara A, Serra V, De Silva P, Hlavata Z, Sangiolo D, Willard-Gallo K, Solinas C. Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Transl Oncol 2020;13:410-22. [PMID: 31901781 DOI: 10.1016/j.tranon.2019.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
567 Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol 2016;12:1439-56. [PMID: 27087632 DOI: 10.2217/fon-2016-0002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
568 Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development. Genes (Basel) 2019;10:E565. [PMID: 31357527 DOI: 10.3390/genes10080565] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
569 Brettrager EJ, van Waardenburg RCAM. Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts. Cancer Drug Resist 2019;2:1153-63. [PMID: 31875206 DOI: 10.20517/cdr.2019.91] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
570 Sato K, Brandsma I, van Rossum-Fikkert SE, Verkaik N, Oostra AB, Dorsman JC, van Gent DC, Knipscheer P, Kanaar R, Zelensky AN. HSF2BP negatively regulates homologous recombination in DNA interstrand crosslink repair. Nucleic Acids Res 2020;48:2442-56. [PMID: 31960047 DOI: 10.1093/nar/gkz1219] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
571 Keka IS, Mohiuddin, Maede Y, Rahman MM, Sakuma T, Honma M, Yamamoto T, Takeda S, Sasanuma H. Smarcal1 promotes double-strand-break repair by nonhomologous end-joining. Nucleic Acids Res 2015;43:6359-72. [PMID: 26089390 DOI: 10.1093/nar/gkv621] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
572 Jiang X, Li W, Li X, Bai H, Zhang Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019;11:4371-90. [PMID: 31191001 DOI: 10.2147/CMAR.S200524] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 23.5] [Reference Citation Analysis]
573 Wang Y, Zheng K, Huang Y, Xiong H, Su J, Chen R, Zou Y. PARP inhibitors in gastric cancer: beacon of hope. J Exp Clin Cancer Res 2021;40:211. [PMID: 34167572 DOI: 10.1186/s13046-021-02005-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
574 Hollis RL, Churchman M, Gourley C. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther 2017;10:2539-51. [PMID: 28546758 DOI: 10.2147/OTT.S102569] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
575 Caron MC, Sharma AK, O'Sullivan J, Myler LR, Ferreira MT, Rodrigue A, Coulombe Y, Ethier C, Gagné JP, Langelier MF, Pascal JM, Finkelstein IJ, Hendzel MJ, Poirier GG, Masson JY. Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nat Commun 2019;10:2954. [PMID: 31273204 DOI: 10.1038/s41467-019-10741-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
576 Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res 2018;78:742-57. [PMID: 29180466 DOI: 10.1158/0008-5472.CAN-17-1494] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
577 Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov 2017;7:20-37. [PMID: 28003236 DOI: 10.1158/2159-8290.CD-16-0860] [Cited by in Crossref: 255] [Cited by in F6Publishing: 136] [Article Influence: 51.0] [Reference Citation Analysis]
578 McMullen M, Karakasis K, Madariaga A, Oza AM. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. Cancers (Basel) 2020;12:E1607. [PMID: 32560564 DOI: 10.3390/cancers12061607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
579 Chen CC, Kass EM, Yen WF, Ludwig T, Moynahan ME, Chaudhuri J, Jasin M. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci U S A 2017;114:7665-70. [PMID: 28659469 DOI: 10.1073/pnas.1706392114] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
580 Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 2014;20:3730-41. [PMID: 24838527 DOI: 10.1158/1078-0432.CCR-13-3446] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
581 Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y. TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. Mol Cancer Ther 2017;16:2543-51. [PMID: 28802254 DOI: 10.1158/1535-7163.MCT-17-0110] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
582 Pascal JM, Ellenberger T. The rise and fall of poly(ADP-ribose): An enzymatic perspective. DNA Repair (Amst) 2015;32:10-6. [PMID: 25963443 DOI: 10.1016/j.dnarep.2015.04.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 10.3] [Reference Citation Analysis]
583 Jdey W, Thierry S, Russo C, Devun F, Al Abo M, Noguiez-Hellin P, Sun JS, Barillot E, Zinovyev A, Kuperstein I, Pommier Y, Dutreix M. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. Clin Cancer Res 2017;23:1001-11. [PMID: 27559053 DOI: 10.1158/1078-0432.CCR-16-1193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 6.4] [Reference Citation Analysis]
584 Krainz T, Lamade AM, Du L, Maskrey TS, Calderon MJ, Watkins SC, Epperly MW, Greenberger JS, Bayır H, Wipf P, Clark RSB. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor. ACS Chem Biol 2018;13:2868-79. [PMID: 30184433 DOI: 10.1021/acschembio.8b00423] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
585 Sakogawa K, Aoki Y, Misumi K, Hamai Y, Emi M, Hihara J, Shi L, Kono K, Horikoshi Y, Sun J, Ikura T, Okada M, Tashiro S. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition. Cancer Sci 2013;104:1593-9. [PMID: 24033642 DOI: 10.1111/cas.12281] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
586 Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz AB, Childers WE, Skorski T, Kolenko V, Tulin AV. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochem Pharmacol 2019;167:149-62. [PMID: 30880062 DOI: 10.1016/j.bcp.2019.03.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
587 Mengwasser KE, Adeyemi RO, Leng Y, Choi MY, Clairmont C, D'Andrea AD, Elledge SJ. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. Mol Cell 2019;73:885-899.e6. [PMID: 30686591 DOI: 10.1016/j.molcel.2018.12.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 32.0] [Reference Citation Analysis]
588 Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 2014;349:408-16. [PMID: 24650937 DOI: 10.1124/jpet.113.210146] [Cited by in Crossref: 152] [Cited by in F6Publishing: 133] [Article Influence: 21.7] [Reference Citation Analysis]
589 Tutt A. Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness. Ann Oncol 2018;29:18-21. [PMID: 29300815 DOI: 10.1093/annonc/mdx775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
590 Nilov D, Maluchenko N, Kurgina T, Pushkarev S, Lys A, Kutuzov M, Gerasimova N, Feofanov A, Švedas V, Lavrik O, Studitsky VM. Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine. Int J Mol Sci 2020;21:E2159. [PMID: 32245127 DOI: 10.3390/ijms21062159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
591 Tuli R, Surmak AJ, Reyes J, Armour M, Hacker-Prietz A, Wong J, DeWeese TL, Herman JM. Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888. Transl Oncol. 2014; Epub ahead of print. [PMID: 24836647 DOI: 10.1016/j.tranon.2014.04.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]